text:
Benzodiazepine
From Wikipedia, the free encyclopedia
Jump to: navigation, search
"Benzo" redirects here. For the derivative drug of benzofuran, see Benzofury.
Benzodiazepines
The core structure of benzodiazepines. "R" labels denote common locations of side chains, which give different benzodiazepines their unique properties.
Pronunciation: /ˌbɛnzoʊdaɪˈæzɪpiːn/
Benzodiazepine
List of benzodiazepines
Benzodiazepine overdose
Benzodiazepine dependence
Benzodiazepine misuse
Benzodiazepine withdrawal syndrome
Effects of long-term benzodiazepine use
v
t
e
Benzodiazepines (BZD, BZs), sometimes called "benzos", are a class of psychoactive drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring. The first such drug, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and made available in 1960 by Hoffmann–La Roche, which, since 1963, has also marketed the benzodiazepine diazepam (Valium).[1] In 1977 benzodiazepines were globally the most prescribed medications.[2] They are in the family of drugs commonly known as minor tranquilizers.[3]
Benzodiazepines enhance the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor, resulting in sedative, hypnotic (sleep-inducing), anxiolytic (anti-anxiety), anticonvulsant, and muscle relaxant properties. High doses of many shorter-acting benzodiazepines may also cause anterograde amnesia and dissociation.[4] These properties make benzodiazepines useful in treating anxiety, insomnia, agitation, seizures, muscle spasms, alcohol withdrawal and as a premedication for medical or dental procedures.[5] Benzodiazepines are categorized as either short-, intermediate-, or long-acting. Short- and intermediate-acting benzodiazepines are preferred for the treatment of insomnia; longer-acting benzodiazepines are recommended for the treatment of anxiety.[6]
Benzodiazepines are generally viewed as safe and effective for short-term use, although cognitive impairment and paradoxical effects such as aggression or behavioral disinhibition occasionally occur. A minority of people can have paradoxical reactions such as worsened agitation or panic.[7] Benzodiazepines are also associated with increased risk of suicide.[8] Long-term use is controversial because of concerns about adverse psychological and physical effects, decreasing effectiveness, and physical dependence and withdrawal.[9][10] As a result of adverse effects associated with the long-term use of benzodiazepines, withdrawal from benzodiazepines often leads to improved physical and mental health.[11][12] The elderly are at an increased risk of suffering from both short- and long-term adverse effects,[11][13] and as a result, all benzodiazepines are listed in the Beers List of inappropriate medications for older adults.[14]
There is controversy concerning the safety of benzodiazepines in pregnancy. While they are not major teratogens, uncertainty remains as to whether they cause cleft palate in a small number of babies and whether neurobehavioural effects occur as a result of prenatal exposure;[15] they are known to cause withdrawal symptoms in the newborn. Benzodiazepines can be taken in overdoses and can cause dangerous deep unconsciousness. However, they are less toxic than their predecessors, the barbiturates, and death rarely results when a benzodiazepine is the only drug taken. When combined with other central nervous system (CNS) depressants such as alcoholic drinks and opioids, the potential for toxicity and fatal overdose increases.[16][17] Benzodiazepines are commonly misused and taken in combination with other drugs of abuse.[18][19][20]
Contents
[hide]
1 Medical uses
1.1 Panic disorder
1.2 Generalized anxiety disorder
1.3 Insomnia
1.4 Seizures
1.5 Alcohol withdrawal
1.6 Anxiety
1.7 Other indications
2 Contraindications
2.1 Pregnancy
2.2 Elderly
3 Adverse effects
3.1 Cognitive effects
3.2 Paradoxical effects
3.3 Long-term worsening of psychiatric symptoms
3.4 Reinforcement disorders
3.4.1 Tolerance
3.4.2 Withdrawal symptoms and management
3.5 Controversial associations
3.5.1 Dementia
3.5.2 Infections
3.5.3 Cancer
3.5.4 Pancreatitis
4 Overdose
5 Interactions
6 Pharmacology
6.1 Mechanism of action
6.2 Pharmacokinetics
7 Chemistry
7.1 Common types
8 History
9 Society and culture
9.1 Legal status
9.2 Recreational use
10 Veterinary use
11 References
12 External links
Medical uses[edit]
Midazolam 1 & 5 mg/mL injections (US)
See also: List of benzodiazepines
Benzodiazepines possess sedative, hypnotic, anxiolytic, anticonvulsant, muscle relaxant, and amnesic actions,[4][5] which are useful in a variety of indications such as alcohol dependence, seizures, anxiety disorders, panic, agitation, and insomnia. Most are administered orally; however, they can also be given intravenously, intramuscularly, or rectally.[21]:189 In general, benzodiazepines are well-tolerated and are safe and effective drugs in the short term for a wide range of conditions.[22][23] Tolerance can develop to their effects and there is also a risk of dependence, and upon discontinuation a withdrawal syndrome may occur. These factors, combined with other possible secondary effects after prolonged use such as psychomotor, cognitive, or memory impairments, limit their long-term applicability.[24][25] The effects of long-term use or misuse include the tendency to cause or worsen cognitive deficits, depression, and anxiety.[11][13] The College of Physicians and Surgeons of British Columbia recommends discontinuing the usage of benzodiazepines in those on opioids and those who have used them long term.[26]
Panic disorder[edit]
Because of their effectiveness, tolerability, and rapid onset of anxiolytic action, benzodiazepines are frequently used for the treatment of anxiety associated with panic disorder.[27] However, there is disagreement among expert bodies regarding the long-term use of benzodiazepines for panic disorder. The views range from those that hold that benzodiazepines are not effective long-term [28] and that they should be reserved for treatment-resistant cases[29] to that they are as effective in the long term as selective serotonin reuptake inhibitors.[30]
The American Psychiatric Association (APA) guidelines[30] note that, in general, benzodiazepines are well tolerated, and their use for the initial treatment for panic disorder is strongly supported by numerous controlled trials. APA states that there is insufficient evidence to recommend any of the established panic disorder treatments over another. The choice of treatment between benzodiazepines, SSRIs, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants, and psychotherapy should be based on the patient's history, preference, and other individual characteristics. Selective serotonin reuptake inhibitors are likely to be the best choice of pharmacotherapy for many patients with panic disorder, but benzodiazepines are also often used, and some studies suggest that these medications are still used with greater frequency than the SSRIs. One advantage of benzodiazepines is that they alleviate the anxiety symptoms much faster than antidepressants, and therefore may be preferred in patients for whom rapid symptom control is critical. However, this advantage is offset by the possibility of developing benzodiazepine dependence. APA does not recommend benzodiazepines for persons with depressive symptoms or a recent history of substance abuse. The APA guidelines state that, in general, pharmacotherapy of panic disorder should be continued for at least a year, and that clinical experience support continuing benzodiazepine treatment to prevent recurrence. Although major concerns about benzodiazepine tolerance and withdrawal have been raised, there is no evidence for significant dose escalation in patients using benzodiazepines long-term. For many such patients stable doses of benzodiazepines retain their efficacy over several years.[30]
Guidelines issued by the UK-based National Institute for Health and Clinical Excellence (NICE), carried out a systematic review using different methodology and came to a different conclusion. They questioned the accuracy of studies that were not placebo-controlled. And, based on the findings of placebo-controlled studies, they do not recommend use of benzodiazepines beyond two to four weeks, as tolerance and physical dependence develop rapidly, with withdrawal symptoms including rebound anxiety occurring after six weeks or more of use.[28][31] Nevertheless, benzodiazepines are still prescribed for long-term treatment of anxiety disorders, although specific antidepressants and psychological therapies are recommended as the first-line treatment options with the anticonvulsant drug pregabalin indicated as a second- or third-line treatment and suitable for long-term use.[32] NICE stated that long-term use of benzodiazepines for panic disorder with or without agoraphobia is an unlicensed indication, does not have long-term efficacy, and is, therefore, not recommended by clinical guidelines. Psychological therapies such as cognitive behavioural therapy are recommended as a first-line therapy for panic disorder; benzodiazepine use has been found to interfere with therapeutic gains from these therapies.[28]
Benzodiazepines are usually administered orally; however, very occasionally lorazepam or diazepam may be given intravenously for the treatment of panic attacks.[21]
Generalized anxiety disorder[edit]
Benzodiazepines have robust efficacy in the short-term management of generalized anxiety disorder (GAD), but were not shown effective in producing long-term improvement overall.[33] According to National Institute for Health and Clinical Excellence (NICE), benzodiazepines can be used in the immediate management of GAD, if necessary. However, they should not usually be given for longer than 2–4 weeks. The only medications NICE recommends for the longer term management of GAD are antidepressants.[34]
Likewise, Canadian Psychiatric Association (CPA) recommends benzodiazepines alprazolam, bromazepam, lorazepam, and diazepam only as a second-line choice, if the treatment with two different antidepressants was unsuccessful. Although they are second-line agents, benzodiazepines can be used for a limited time to relieve severe anxiety and agitation. CPA guidelines note that after 4–6 weeks the effect of benzodiazepines may decrease to the level of placebo, and that benzodiazepines are less effective than antidepressants in alleviating ruminative worry, the core symptom of GAD. However, in some cases, a prolonged treatment with benzodiazepines as the add-on to an antidepressant may be justified.[35]
A 2015 review found a larger effect with medications than talk therapy.[36] Medications with benefit include serotonin-noradrenaline reuptake inhibitors, benzodiazepines, and selective serotonin reuptake inhibitors.[36]
Insomnia[edit]
Temazepam (Normison) 10 mg tablets
Benzodiazepines can be useful for short-term treatment of insomnia. Their use beyond 2 to 4 weeks is not recommended due to the risk of dependence. It is preferred that benzodiazepines be taken intermittently and at the lowest effective dose. They improve sleep-related problems by shortening the time spent in bed before falling asleep, prolonging the sleep time, and, in general, reducing wakefulness.[37][38] However, they worsen sleep quality by increasing light sleep and decreasing deep sleep. Other drawbacks of hypnotics, including benzodiazepines, are possible tolerance to their effects, rebound insomnia, and reduced slow-wave sleep and a withdrawal period typified by rebound insomnia and a prolonged period of anxiety and agitation.[39][40]
The list of benzodiazepines approved for the treatment of insomnia is fairly similar among most countries, but which benzodiazepines are officially designated as first-line hypnotics prescribed for the treatment of insomnia varies between countries.[38] Longer-acting benzodiazepines such as nitrazepam and diazepam have residual effects that may persist into the next day and are, in general, not recommended.[37]
Since the release of nonbenzodiazepines in 1992 in response to safety concerns, individuals with insomnia and other sleep disorders have increasingly been prescribed nonbenzodiazepines (2.3% in 1993 to 13.7% of Americans in 2010), less often prescribed benzodiazepines (23.5% in 1993 to 10.8% in 2010).[41][42] It is not clear as to whether the new nonbenzodiazepine hypnotics (Z-drugs) are better than the short-acting benzodiazepines. The efficacy of these two groups of medications is similar.[37][40] According to the US Agency for Healthcare Research and Quality, indirect comparison indicates that side-effects from benzodiazepines may be about twice as frequent as from nonbenzodiazepines.[40] Some experts suggest using nonbenzodiazepines preferentially as a first-line long-term treatment of insomnia.[38] However, the UK National Institute for Health and Clinical Excellence did not find any convincing evidence in favor of Z-drugs. NICE review pointed out that short-acting Z-drugs were inappropriately compared in clinical trials with long-acting benzodiazepines. There have been no trials comparing short-acting Z-drugs with appropriate doses of short-acting benzodiazepines. Based on this, NICE recommended choosing the hypnotic based on cost and the patient's preference.[37]
Older adults should not use benzodiazepines to treat insomnia unless other treatments have failed.[43] When benzodiazepines are used, patients, their caretakers, and their physician should discuss the increased risk of harms, including evidence that shows twice the incidence of traffic collisions among driving patients, and falls and hip fracture for older patients.[43]
Seizures[edit]
Prolonged convulsive epileptic seizures are a medical emergency that can usually be dealt with effectively by administering fast-acting benzodiazepines, which are potent anticonvulsants. In a hospital environment, intravenous clonazepam, lorazepam, and diazepam are first-line choices, clonazepam due to its stronger and more potent anticonvulsant action, diazepam due to its faster onset and lorazepam for its longer duration of action. In the community, intravenous administration is not practical and so rectal diazepam or (more recently) buccal midazolam are used, with a preference for midazolam as its administration is easier and more socially acceptable.[44][45]
When benzodiazepines were first introduced, they were enthusiastically adopted for treating all forms of epilepsy. However, drowsiness and tolerance become problems with continued use and none are now considered first-line choices for long-term epilepsy therapy.[46] Clobazam is widely used by specialist epilepsy clinics worldwide and clonazepam is popular in the Netherlands, Belgium and France.[46] Clobazam was approved for use in the United States in 2011. In the UK, both clobazam and clonazepam are second-line choices for treating many forms of epilepsy.[47] Clobazam also has a useful role for very short-term seizure prophylaxis and in catamenial epilepsy.[46] Discontinuation after long-term use in epilepsy requires additional caution because of the risks of rebound seizures. Therefore, the dose is slowly tapered over a period of up to six months or longer.[45]
Alcohol withdrawal[edit]
Chlordiazepoxide is the most commonly used benzodiazepine for alcohol detoxification,[48] but diazepam may be used as an alternative. Both are used in the detoxification of individuals who are motivated to stop drinking, and are prescribed for a short period of time to reduce the risks of developing tolerance and dependence to the benzodiazepine medication itself.[21]:275 The benzodiazepines with a longer half-life make detoxification more tolerable, and dangerous (and potentially lethal) alcohol withdrawal effects are less likely to occur. On the other hand, short-acting benzodiazepines may lead to breakthrough seizures, and are, therefore, not recommended for detoxification in an outpatient setting. Oxazepam and lorazepam are often used in patients at risk of drug accumulation, in particular, the elderly and those with cirrhosis, because they are metabolized differently from other benzodiazepines, through conjugation.[49][50]
Benzodiazepines are the preferred choice in the management of alcohol withdrawal syndrome, in particular, for the prevention and treatment of the dangerous complication of seizures and in subduing severe delirium.[51] Lorazepam is the only benzodiazepine with predictable intramuscular absorption and it is the most effective in preventing and controlling acute seizures.[52]
Anxiety[edit]
Benzodiazepines are sometimes used in the treatment of acute anxiety, as they bring about rapid and marked or moderate relief of symptoms in most individuals;[28] however, they are not recommended beyond 2–4 weeks of use due to risks of tolerance and dependence and a lack of long-term effectiveness. As for insomnia, they may also be used on an irregular/"as-needed" basis, such as in cases where said anxiety is at its worst. Compared to other pharmacological treatments, benzodiazepines are twice as likely to lead to a relapse of the underlying condition upon discontinuation. Psychological therapies and other pharmacological therapies are recommended for the long-term treatment of generalized anxiety disorder. Antidepressants have higher remission rates and are, in general, safe and effective in the short and long term.[28]
Other indications[edit]
Benzodiazepines are often prescribed for a wide range of conditions:
They can be very useful in intensive care to sedate patients receiving mechanical ventilation or those in extreme distress. Caution is exercised in this situation due to the occasional occurrence of respiratory depression, and it is recommended that benzodiazepine overdose treatment facilities should be available.[53]
Benzodiazepines are effective as medication given a couple of hours before surgery to relieve anxiety. They also produce amnesia, which can be useful, as patients may not remember unpleasantness from the procedure.[54] They are also used in patients with dental phobia as well as some ophthalmic procedures like refractive surgery; although such use is controversial and only recommended for those who are very anxious.[55] Midazolam is the most commonly prescribed for this use because of its strong sedative actions and fast recovery time, as well as its water solubility, which reduces pain upon injection. Diazepam and lorazepam are sometimes used. Lorazepam has particularly marked amnesic properties that may make it more effective when amnesia is the desired effect.[21]:693
Benzodiazepines are well known for their strong muscle-relaxing properties and can be useful in the treatment of muscle spasms,[21]:577–578 although tolerance often develops to their muscle relaxant effects.[11] Baclofen[56] or tizanidine are sometimes used as an alternative to benzodiazepines. Tizanidine has been found to have superior tolerability compared to diazepam and baclofen.[57]
Benzodiazepines are also used to treat the acute panic caused by hallucinogen intoxication.[58] Benzodiazepines are also used to calm the acutely agitated individual and can, if required, be given via an intramuscular injection.[59] They can sometimes be effective in the short-term treatment of psychiatric emergencies such as acute psychosis as in schizophrenia or mania, bringing about rapid tranquillization and sedation until the effects of lithium or neuroleptics (antipsychotics) take effect. Lorazepam is most commonly used but clonazepam is sometimes prescribed for acute psychosis or mania;[60] their long-term use is not recommended due to risks of dependence.[21]:204 Further research investigating the use of benzodiazepines alone and in combination with antipsychotic medications for treating acute psychosis is warranted.[61]
Clonazepam, a benzodiazepine is used to treat many forms of parasomnia.[62] Rapid eye movement behavior disorder responds well to low doses of clonazepam.[63][64] Restless legs syndrome can be treated using clonazepam as a third line treatment option as the use of clonazepam is still investigational.[65][66]
Benzodiazepines are sometimes used for obsessive–compulsive disorder (OCD), although they are generally believed ineffective for this indication. Effectiveness was, however, found in one small study.[67] Benzodiazepines can be considered as a treatment option in treatment resistant cases.[68]
Antipsychotics are generally a first-line treatment for delirium; however, when delirium is caused by alcohol or sedative hypnotic withdrawal, benzodiazepines are a first-line treatment.[69]
There is some evidence that low doses of benzodiazepines reduce adverse effects of electroconvulsive therapy.[70]
Contraindications[edit]
Because of their muscle relaxant action, benzodiazepines may cause respiratory depression in susceptible individuals. For that reason, they are contraindicated in people with myasthenia gravis, sleep apnea, bronchitis, and COPD.[71][72] Caution is required when benzodiazepines are used in people with personality disorders or intellectual disability because of frequent paradoxical reactions.[71][72] In major depression, they may precipitate suicidal tendencies[73] and are sometimes used for suicidal overdoses.[72] Individuals with a history of alcohol, opioid and barbiturate abuse should avoid benzodiazepines, as there is a risk of life-threatening interactions with these drugs.[74]
Pregnancy[edit]
See also: Effects of benzodiazepines on newborns
In the United States, the Food and Drug Administration has categorized benzodiazepines into either category D or X meaning potential for harm in the unborn has been demonstrated.[75]
Exposure to benzodiazepines during pregnancy has been associated with a slightly increased (from 0.06 to 0.07%) risk of cleft palate in newborns, a controversial conclusion as some studies find no association between benzodiazepines and cleft palate. Their use by expectant mothers shortly before the delivery may result in a floppy infant syndrome, with the newborns suffering from hypotonia, hypothermia, lethargy, and breathing and feeding difficulties.[15][76] Cases of neonatal withdrawal syndrome have been described in infants chronically exposed to benzodiazepines in utero. This syndrome may be hard to recognize, as it starts several days after delivery, for example, as late as 21 days for chlordiazepoxide. The symptoms include tremors, hypertonia, hyperreflexia, hyperactivity, and vomiting and may last for up to three to six months.[15][77] Tapering down the dose during pregnancy may lessen its severity. If used in pregnancy, those benzodiazepines with a better and longer safety record, such as diazepam or chlordiazepoxide, are recommended over potentially more harmful benzodiazepines, such as temazepam[78] or triazolam. Using the lowest effective dose for the shortest period of time minimizes the risks to the unborn child.[79]
Elderly[edit]
The benefits of benzodiazepines are least and the risks are greatest in the elderly.[80][81] The elderly are at an increased risk of dependence and are more sensitive to the adverse effects such as memory problems, daytime sedation, impaired motor coordination, and increased risk of motor vehicle accidents and falls,[82] and an increased risk of hip fractures.[83] The long-term effects of benzodiazepines and benzodiazepine dependence in the elderly can resemble dementia, depression, or anxiety syndromes, and progressively worsens over time. Adverse effects on cognition can be mistaken for the effects of old age. The benefits of withdrawal include improved cognition, alertness, mobility, reduced risk incontinence, and a reduced risk of falls and fractures. The success of gradual-tapering benzodiazepines is as great in the elderly as in younger people. Benzodiazepines should be prescribed to the elderly only with caution and only for a short period at low doses.[84][85] Short to intermediate-acting benzodiazepines are preferred in the elderly such as oxazepam and temazepam. The high potency benzodiazepines alprazolam and triazolam and long-acting benzodiazepines are not recommended in the elderly due to increased adverse effects. Nonbenzodiazepines such as zaleplon and zolpidem and low doses of sedating antidepressants are sometimes used as alternatives to benzodiazepines.[85][86]
Long-term use of benzodiazepines has been associated with increased risk of cognitive impairment, but its relationship with dementia remains inconclusive.[87] The association of a past history of benzodiazepine use and cognitive decline is unclear, with some studies reporting a lower risk of cognitive decline in former users, some finding no association and some indicating an increased risk of cognitive decline.[88]
Benzodiazepines are sometimes prescribed to treat behavioral symptoms of dementia. However, like antidepressants, they have little evidence of effectiveness, although antipsychotics have shown some benefit.[89][90] Cognitive impairing effects of benzodiazepines that occur frequently in the elderly can also worsen dementia.[91]
Adverse effects[edit]
Addiction experts in psychiatry, chemistry, pharmacology, forensic science, epidemiology, and the police and legal services engaged in delphic analysis regarding 20 popular recreational drugs. Benzodiazepines were ranked 7th in dependence, physical harm, and social harm.[92]
See also: Long-term effects of benzodiazepines, Paradoxical reaction § Benzodiazepines, and benzodiazepine withdrawal syndrome
The most common side-effects of benzodiazepines are related to their sedating and muscle-relaxing action. They include drowsiness, dizziness, and decreased alertness and concentration. Lack of coordination may result in falls and injuries, in particular, in the elderly.[71][93][94] Another result is impairment of driving skills and increased likelihood of road traffic accidents.[95][96] Decreased libido and erection problems are a common side effect. Depression and disinhibition may emerge. Hypotension and suppressed breathing (hypoventilation) may be encountered with intravenous use.[71][93] Less common side effects include nausea and changes in appetite, blurred vision, confusion, euphoria, depersonalization and nightmares. Cases of liver toxicity have been described but are very rare.[21]:183–189[97]
The long-term effects of benzodiazepine use can include cognitive impairment as well as affective and behavioural problems. Feelings of turmoil, difficulty in thinking constructively, loss of sex-drive, agoraphobia and social phobia, increasing anxiety and depression, loss of interest in leisure pursuits and interests, and an inability to experience or express feelings can also occur. Not everyone, however, experiences problems with long-term use.[12][98] Additionally, an altered perception of self, environment and relationships may occur.[99]
Cognitive effects[edit]
The short-term use of benzodiazepines adversely affects multiple areas of cognition, the most notable one being that it interferes with the formation and consolidation of memories of new material and may induce complete anterograde amnesia.[71] However, researchers hold contrary opinions regarding the effects of long-term administration. One view is that many of the short-term effects continue into the long-term and may even worsen, and are not resolved after stopping benzodiazepine usage. Another view maintains that cognitive deficits in chronic benzodiazepine users occur only for a short period after the dose, or that the anxiety disorder is the cause of these deficits.
While the definitive studies are lacking, the former view received support from a 2004 meta-analysis of 13 small studies.[99][100] This meta-analysis found that long-term use of benzodiazepines was associated with moderate to large adverse effects on all areas of cognition, with visuospatial memory being the most commonly detected impairment. Some of the other impairments reported were decreased IQ, visiomotor coordination, information processing, verbal learning and concentration. The authors of the meta-analysis[100] and a later reviewer[99] noted that the applicability of this meta-analysis is limited because the subjects were taken mostly from withdrawal clinics; the coexisting drug, alcohol use, and psychiatric disorders were not defined; and several of the included studies conducted the cognitive measurements during the withdrawal period.
Paradoxical effects[edit]
Paradoxical reactions, such as increased seizures in epileptics,[101] aggression, violence, impulsivity, irritability and suicidal behavior sometimes occur.[8] These reactions have been explained as consequences of disinhibition and the subsequent loss of control over socially unacceptable behavior. Paradoxical reactions are rare in the general population, with an incidence rate below 1% and similar to placebo.[7][102] However, they occur with greater frequency in recreational abusers, individuals with borderline personality disorder, children, and patients on high-dosage regimes.[103][104] In these groups, impulse control problems are perhaps the most important risk factor for disinhibition; learning disabilities and neurological disorders are also significant risks. Most reports of disinhibition involve high doses of high-potency benzodiazepines.[102] Paradoxical effects may also appear after chronic use of benzodiazepines.[105]
Long-term worsening of psychiatric symptoms[edit]
While benzodiazepines may have short-term benefits for anxiety, sleep and agitation in some patients, long-term (i.e., greater than 2–4 weeks) use can result in a worsening of the very symptoms the medications are meant to treat. Potential explanations include exacerbating cognitive problems that are already common in anxiety disorders, causing or worsening depression and suicidality,[106][107] disrupting sleep architecture by inhibiting deep stage sleep,[108] withdrawal symptoms or rebound symptoms in between doses mimicking or exacerbating underlying anxiety or sleep disorders,[106][107] inhibiting the benefits of psychotherapy by inhibiting memory consolidation and reducing fear extinction,[109][110][111] and reducing coping with trauma/stress and increasing vulnerability to future stress.[112] Anxiety, insomnia and irritability may be temporarily exacerbated during withdrawal, but psychiatric symptoms after discontinuation are usually less than even while taking benzodiazepines.[106][113] Fortunately, for those with benzodiazepine-induced problems, functioning significantly improves within 1 year of discontinuation.[106][114]
Reinforcement disorders[edit]
Diazepam 2 mg and 5 mg diazepam tablets, which are commonly used in the treatment of benzodiazepine withdrawal.
Main articles: Benzodiazepine dependence, Benzodiazepine withdrawal syndrome, and post-acute withdrawal syndrome
Tolerance[edit]
The main problem of the chronic use of benzodiazepines is the development of tolerance and dependence. Tolerance manifests itself as diminished pharmacological effect and develops relatively quickly to the sedative, hypnotic, anticonvulsant, and muscle relaxant actions of benzodiazepines. Tolerance to anti-anxiety effects develops more slowly with little evidence of continued effectiveness beyond four to six months of continued use.[11] In general, tolerance to the amnesic effects does not occur.[91] However, controversy exists as to tolerance to the anxiolytic effects with some evidence that benzodiazepines retain efficacy[115] and opposing evidence from a systematic review of the literature that tolerance frequently occurs[22][28] and some evidence that anxiety may worsen with long-term use.[11] The question of tolerance to the amnesic effects of benzodiazepines is, likewise, unclear.[116] Some evidence suggests that partial tolerance does develop, and that, "memory impairment is limited to a narrow window within 90 minutes after each dose".[117]
A major disadvantage of benzodiazepines that tolerance to therapeutic effects develops relatively quickly while many adverse effects persist. Tolerance develops to hypnotic and myorelexant effects within days to weeks, and to anticonvulsant and anxiolytic effects within weeks to months.[106] Therefore, benzodiazepines are unlikely to be effective long-term treatments for sleep and anxiety. While BZD therapeutic effects disappear with tolerance, depression and impulsivity with high suicidal risk commonly persist.[106] Several studies have confirmed that long-term benzodiazepines are not significantly different from placebo for sleep[118][119][120] or anxiety.[106][121][122][123] This may explain why patients commonly increase doses over time and many eventually take more than one type of benzodiazepine after the first loses effectiveness.[108][124][125] Additionally, because tolerance to benzodiazepine sedating effects develops more quickly than does tolerance to brainstem depressant effects, those taking more benzodiazepines to achieve desired effects may suffer sudden respiratory depression, hypotension or death.[126] Most patients with anxiety disorders and PTSD have symptoms that persist for at least several months,[126] making tolerance to therapeutic effects a distinct problem for them and necessitating the need for more effective long-term treatment (e.g., psychotherapy, serotonergic antidepressants).
Withdrawal symptoms and management[edit]
Chlordiazepoxide 5 mg capsules, which are sometimes used as an alternative to diazepam for benzodiazepine withdrawal. Like diazepam it has a long elimination half-life and long-acting active metabolites.
Discontinuation of benzodiazepines or abrupt reduction of the dose, even after a relatively short course of treatment (three to four weeks), may result in two groups of symptoms—rebound and withdrawal. Rebound symptoms are the return of the symptoms for which the patient was treated but worse than before. Withdrawal symptoms are the new symptoms that occur when the benzodiazepine is stopped. They are the main sign of physical dependence.[117]
The most frequent symptoms of withdrawal from benzodiazepines are insomnia, gastric problems, tremors, agitation, fearfulness, and muscle spasms.[117] The less frequent effects are irritability, sweating, depersonalization, derealization, hypersensitivity to stimuli, depression, suicidal behavior, psychosis, seizures, and delirium tremens.[127] Severe symptoms usually occur as a result of abrupt or over-rapid withdrawal. Abrupt withdrawal can be dangerous, therefore a gradual reduction regimen is recommended.[10]
Symptoms may also occur during a gradual dosage reduction, but are typically less severe and may persist as part of a protracted withdrawal syndrome for months after cessation of benzodiazepines.[128] Approximately 10% of patients experience a notable protracted withdrawal syndrome, which can persist for many months or in some cases a year or longer. Protracted symptoms tend to resemble those seen during the first couple of months of withdrawal but usually are of a sub-acute level of severity. Such symptoms do gradually lessen over time, eventually disappearing altogether.[129]
Benzodiazepines have a reputation with patients and doctors for causing a severe and traumatic withdrawal; however, this is in large part due to the withdrawal process being poorly managed. Over-rapid withdrawal from benzodiazepines increases the severity of the withdrawal syndrome and increases the failure rate. A slow and gradual withdrawal customised to the individual and, if indicated, psychological support is the most effective way of managing the withdrawal. Opinion as to the time needed to complete withdrawal ranges from four weeks to several years. A goal of less than six months has been suggested,[10] but due to factors such as dosage and type of benzodiazepine, reasons for prescription, lifestyle, personality, environmental stresses, and amount of available support, a year or more may be needed to withdraw.[11][21]:183–184
Withdrawal is best managed by transferring the physically dependent patient to an equivalent dose of diazepam because it has the longest half-life of all of the benzodiazepines, is metabolised into long-acting active metabolites and is available in low-potency tablets, which can be quartered for smaller doses.[130] A further benefit is that it is available in liquid form, which allows for even smaller reductions.[10] Chlordiazepoxide, which also has a long half-life and long-acting active metabolites, can be used as an alternative.[130][131]
Nonbenzodiazepines are contraindicated during benzodiazepine withdrawal as they are cross tolerant with benzodiazepines and can induce dependence.[11] Alcohol is also cross tolerant with benzodiazepines and more toxic and thus caution is needed to avoid replacing one dependence with another.[130] During withdrawal, fluoroquinolone-based antibiotics are best avoided if possible; they displace benzodiazepines from their binding site and reduce GABA function and, thus, may aggravate withdrawal symptoms.[132] Antipsychotics are not recommended for benzodiazepine withdrawal (or other CNS depressant withdrawal states) especially clozapine, olanzapine or low potency phenothiazines e.g. chlorpromazine as they lower the seizure threshold and can worsen withdrawal effects; if used extreme caution is required.[133]
Withdrawal from long term benzodiazepines is beneficial for most individuals.[105] Withdrawal of benzodiazepines from long-term users, in general, leads to improved physical and mental health particularly in the elderly; although some long term users report continued benefit from taking benzodiazepines, this may be the result of suppression of withdrawal effects.[11][12]
Controversial associations[edit]
Beyond the well established link between benzodiazepines and psychomotor impairment resulting in motor vehicle accidents and falls leading to fracture; research in the 2000's and 2010's has raised the association between benzodiazepines (and Z-Drugs) and other, as of yet unproven, adverse effects including dementia, cancer, infections, pancreatitis and respiratory disease exacerbations.[134]
Dementia[edit]
A number of studies have drawn an association between long-term benzodiazepine use and neuro-degenerative disease, particularly Alzheimer's disease.[135] However, most of these studies have been retrospective and observational thus limiting the confidence in causal inference. Expert critics of this body of research have consistently speculated that the association may be attributable to protopathic bias or confounding by indication, whereby individuals experiencing early stages of dementia (or who have been previously diagnosed) are prescribed benzodiazepines to manage agitation and behavioral disturbance.[136][137] Further evidence from a large prospective study of long follow-up duration along with neuro-pharmacological research is needed to confirm or refute this association.[137]
Infections[edit]
Some observational studies have detected significant associations between benzodiazepines and respiratory infections such as pneumonia[138][139] where others have not.[140] A large meta-analysis of pre-marketing randomized controlled trials on the pharmacologically related Z-Drugs suggest a small increase in infection risk as well.[141] An immunodeficiency effect from the action of benzodiazepines on GABA-A receptors has been postulated from animal studies.[142][143]
Cancer[edit]
A Meta-analysis of observational studies has determined an association between benzodiazepine use and cancer, though the risk across different agents and different cancers varied significantly.[144] Furthermore, most of these studies were unable to control for confounding variables that may have influenced the relationship such as lifestyle exposures (i.e tobacco, alcohol). In terms of experimental basic science evidence, an analysis of carcinogenetic and genotoxicity data for various benzodiazepines has suggested a small possibility of carcinogenesis for a small number of benzodiazepines.[145] A large, properly designed randomized controlled trial with appropriate follow-up in addition to further pharmacologic/toxicologic investigation is needed to confirm these preliminary findings.
Pancreatitis[edit]
The evidence suggesting a link between benzodiazepines (and Z-Drugs) and pancreatic inflammation is very sparse and limited to a few observational studies from Taiwan.[146][147] A criticism of confounding can be applied to these findings as with the other controversial associations above. Further well-designed research from other populations as well as a biologically plausible mechanism is required to confirm this association.
Overdose[edit]
US yearly overdose deaths involving benzodiazepines.[148]
Red line represents the number of benzodiazepine deaths that also involved opioids in the US, and the purple line represents benzodiazepine deaths that did not involve opioids.[148]
The use of flumazenil is controversial following benzodiazepine overdose.
Main article: Benzodiazepine overdose
Although benzodiazepines are much safer in overdose than their predecessors, the barbiturates, they can still cause problems in overdose.[16] Taken alone, they rarely cause severe complications in overdose;[149] statistics in England showed that benzodiazepines were responsible for 3.8% of all deaths by poisoning from a single drug.[18] However, combining these drugs with alcohol, opiates or tricyclic antidepressants markedly raises the toxicity.[19][150][151] The elderly are more sensitive to the side effects of benzodiazepines, and poisoning may even occur from their long-term use.[152] The various benzodiazepines differ in their toxicity; temazepam appears most toxic in overdose and when used with other drugs.[153][154] The symptoms of a benzodiazepine overdose may include; drowsiness, slurred speech, nystagmus, hypotension, ataxia, coma, respiratory depression, and cardiorespiratory arrest.[151]
A reversal agent for benzodiazepines exists, flumazenil (Anexate). Its use as an antidote is not routinely recommended because of the high risk of resedation and seizures.[155] In a double-blind, placebo-controlled trial of 326 people, 4 people had serious adverse events and 61% became resedated following the use of flumazenil.[156] Numerous contraindications to its use exist. It is contraindicated in people with a history of long-term use of benzodiazepines, those having ingested a substance that lowers the seizure threshold or may cause an arrhythmia, and in those with abnormal vital signs.[157] One study found that only 10% of the people presenting with a benzodiazepine overdose are suitable candidates for treatment with flumazenil.[158]
Interactions[edit]
Individual benzodiazepines may have different interactions with certain drugs. Depending on their metabolism pathway, benzodiazepines can be divided roughly into two groups. The largest group consists of those that are metabolized by cytochrome P450 (CYP450) enzymes and possess significant potential for interactions with other drugs. The other group comprises those that are metabolized through glucuronidation, such as lorazepam, oxazepam, and temazepam, and, in general, have few drug interactions.[72]
Many drugs, including oral contraceptives, some antibiotics, antidepressants, and antifungal agents, inhibit cytochrome enzymes in the liver. They reduce the rate of elimination of the benzodiazepines that are metabolized by CYP450, leading to possibly excessive drug accumulation and increased side-effects. In contrast, drugs that induce cytochrome P450 enzymes, such as St John's wort, the antibiotic rifampicin, and the anticonvulsants carbamazepine and phenytoin, accelerate elimination of many benzodiazepines and decrease their action.[74][159] Taking benzodiazepines with alcohol, opioids and other central nervous system depressants potentiates their action. This often results in increased sedation, impaired motor coordination, suppressed breathing, and other adverse effects that have potential to be lethal.[74][159] Antacids can slow down absorption of some benzodiazepines; however, this effect is marginal and inconsistent.[74]
Pharmacology[edit]
Mechanism of action[edit]
Schematic diagram of the (α1)2(β2)2(γ2) GABAA receptor complex that depicts the five-protein subunits that form the receptor, the chloride (Cl−) ion channel pore at the center, the two GABA active binding sites at the α1 and β2 interfaces and the benzodiazepine (BZD) allosteric binding site at the α1 and γ2 interface.
Benzodiazepines work by increasing the efficiency of a natural brain chemical, GABA, to decrease the excitability of neurons. This reduces the communication between neurons and, therefore, has a calming effect on many of the functions of the brain.
GABA controls the excitability of neurons by binding to the GABAA receptor.[160] The GABAA receptor is a protein complex located in the synapses of neurons. All GABAA receptors contain an ion channel that conducts chloride ions across neuronal cell membranes and two binding sites for the neurotransmitter gamma-aminobutyric acid (GABA), while a subset of GABAA receptor complexes also contain a single binding site for benzodiazepines. Binding of benzodiazepines to this receptor complex does not alter binding of GABA. Unlike other positive allosteric modulators that increases ligand binding, benzodiazepine binding acts as a positive allosteric modulator by increasing the total conduction of chloride ions across the neuronal cell membrane when GABA is already bound to its receptor. This increased chloride ion influx hyperpolarizes the neuron's membrane potential. As a result, the difference between resting potential and threshold potential is increased and firing is less likely. Different GABAA receptor subtypes have varying distributions within different regions of the brain and, therefore, control distinct neuronal circuits. Hence, activation of different GABAA receptor subtypes by benzodiazepines may result in distinct pharmacological actions.[161] In terms of the mechanism of action of benzodiazepines, their similarities are too great to separate them into individual categories such as anxiolytic or hypnotic. For example, a hypnotic administered in low doses produces anxiety-relieving effects, whereas a benzodiazepine marketed as an anti-anxiety drug at higher doses induces sleep.[162]
The subset of GABAA receptors that also bind benzodiazepines are referred to as benzodiazepine receptors (BzR). The GABAA receptor is a heteromer composed of five subunits, the most common ones being two αs, two βs, and one γ (α2β2γ). For each subunit, many subtypes exist (α1–6, β1–3, and γ1–3). GABAA receptors that are made up of different combinations of subunit subtypes have different properties, different distributions in the brain and different activities relative to pharmacological and clinical effects.[163] Benzodiazepines bind at the interface of the α and γ subunits on the GABAA receptor. Binding also requires that alpha subunits contain a histidine amino acid residue, (i.e., α1, α2, α3, and α5 containing GABAA receptors). For this reason, benzodiazepines show no affinity for GABAA receptors containing α4 and α6 subunits with an arginine instead of a histidine residue.[164] Once bound to the benzodiazepine receptor, the benzodiazepine ligand locks the benzodiazepine receptor into a conformation in which it has a greater affinity for the GABA neurotransmitter. This increases the frequency of the opening of the associated chloride ion channel and hyperpolarizes the membrane of the associated neuron. The inhibitory effect of the available GABA is potentiated, leading to sedatory and anxiolytic effects. For instance, those ligands with high activity at the α1 are associated with stronger hypnotic effects, whereas those with higher affinity for GABAA receptors containing α2 and/or α3 subunits have good anti-anxiety activity.[165]
The benzodiazepine class of drugs also interact with peripheral benzodiazepine receptors. Peripheral benzodiazepine receptors are present in peripheral nervous system tissues, glial cells, and to a lesser extent the central nervous system.[166] These peripheral receptors are not structurally related or coupled to GABAA receptors. They modulate the immune system and are involved in the body response to injury.[167][168] Benzodiazepines also function as weak adenosine reuptake inhibitors. It has been suggested that some of their anticonvulsant, anxiolytic, and muscle relaxant effects may be in part mediated by this action.[169]
Pharmacokinetics[edit]
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. (May 2015)
Benzodiazepine
Half-life
(range, hours)
Speed of Onset
Alprazolam 7001120000000000000♠12–15[170] Intermediate[170]
Flunitrazepam 7001180000000000000♠18-26 Intermediate
Chlordiazepoxide 7001100000000000000♠10–30[170] Intermediate[170]
Clonazepam 7001190000000000000♠19–60[170] Slow[170]
Diazepam 7001200000000000000♠20–80[170] Fast[170]
Lorazepam 7001100000000000000♠10–20[170] Intermediate[170]
Midazolam 7000150000000000000♠1.5-2.5[171] Fast
Oxazepam 7000500000000000000♠5–10[170] Slow[170]
Prazepam 7001500000000000000♠50–200[170] Slow[170]
A benzodiazepine can be placed into one of three groups by its elimination half-life, or time it takes for the body to eliminate half of the dose.[172] Some benzodiazepines have long-acting active metabolites, such as diazepam and chlordiazepoxide, which are metabolised into desmethyldiazepam. Desmethyldiazepam has a half-life of 36–200 hours, and flurazepam, with the main active metabolite of desalkylflurazepam, with a half-life of 40–250 hours. These long-acting metabolites are partial agonists.[6][130]
Short-acting compounds have a median half-life of 1–12 hours. They have few residual effects if taken before bedtime, rebound insomnia may occur upon discontinuation, and they might cause daytime withdrawal symptoms such as next day rebound anxiety with prolonged usage. Examples are brotizolam, midazolam, and triazolam.
Intermediate-acting compounds have a median half-life of 12–40 hours. They may have some residual effects in the first half of the day if used as a hypnotic. Rebound insomnia, however, is more common upon discontinuation of intermediate-acting benzodiazepines than longer-acting benzodiazepines. Examples are alprazolam, estazolam, flunitrazepam, clonazepam, lormetazepam, lorazepam, nitrazepam, and temazepam.
Long-acting compounds have a half-life of 40–250 hours. They have a risk of accumulation in the elderly and in individuals with severely impaired liver function, but they have a reduced severity of rebound effects and withdrawal. Examples are diazepam, clorazepate, chlordiazepoxide, and flurazepam.
Chemistry[edit]
Left: The 1,4-benzodiazepine ring system. Right: 5-phenyl-1H-benzo[e] [1,4]diazepin-2(3H)-one forms the skeleton of many of the most common benzodiazepine pharmaceuticals, such as diazepam (7-chloro-1-methyl substituted).
A pharmacophore model of the benzodiazepine binding site on the GABAA receptor.[173] White sticks represent the carbon atoms of the benzodiazepine diazepam, while green represents carbon atoms of the nonbenzodiazepine CGS-9896. Red and blue sticks are oxygen and nitrogen atoms that are present in both structures. The red spheres labeled H1 and H2/A3 are, respectively, hydrogen bond donating and accepting sites in the receptor, while L1, L2, and L3 denote lipophilic binding sites.
Benzodiazepines share a similar chemical structure, and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the overall conductance of these inhibitory channels; this results in the various therapeutic effects as well as adverse effects of benzodiazepines.[160] Other less important mechanisms of action are also known.[167][169]
The term benzodiazepine is the chemical name for the heterocyclic ring system (see figure to the right), which is a fusion between the benzene and diazepine ring systems.[174] Under Hantzsch–Widman nomenclature, a diazepine is a heterocycle with two nitrogen atoms, five carbon atom and the maximum possible number of cumulative double bonds. The "benzo" prefix indicates the benzene ring fused onto the diazepine ring.[174]
Benzodiazepine drugs are substituted 1,4-benzodiazepines, although the chemical term can refer to many other compounds that do not have useful pharmacological properties. Different benzodiazepine drugs have different side groups attached to this central structure. The different side groups affect the binding of the molecule to the GABAA receptor and so modulate the pharmacological properties.[160] Many of the pharmacologically active "classical" benzodiazepine drugs contain the 5-phenyl-1H-benzo[e] [1,4]diazepin-2(3H)-one substructure (see figure to the right).[175] Benzodiazepines have been found to mimic protein reverse turns structurally, which enable them with their biological activity in many cases.[176][177]
Nonbenzodiazepines also bind to the benzodiazepine binding site on the GABAA receptor and possess similar pharmacological properties. While the nonbenzodiazepines are by definition structurally unrelated to the benzodiazepines, both classes of drugs possess a common pharmacophore (see figure to the lower-right), which explains their binding to a common receptor site.[173]
Common types[edit]
2-keto compounds:
clorazepate, diazepam, flurazepam, halazepam, prazepam, and others.[178][179]
3-hydroxy compounds:
lorazepam, lormetazepam, oxazepam, temazepam[178][179]
7-nitro compounds:
clonazepam, flunitrazepam, nimetazepam, nitrazepam[178][179]
Triazolo compounds:
adinazolam, alprazolam, estazolam, triazolam[178][179]
Imidazo compounds
climazolam, loprazolam, midazolam[178][179]
History[edit]
The molecular structure of chlordiazepoxide, the first benzodiazepine. It was marketed by Hoffmann–La Roche from 1960 branded as Librium.
The first benzodiazepine, chlordiazepoxide (Librium), was synthesized in 1955 by Leo Sternbach while working at Hoffmann–La Roche on the development of tranquilizers. The pharmacological properties of the compounds prepared initially were disappointing, and Sternbach abandoned the project. Two years later, in April 1957, co-worker Earl Reeder noticed a "nicely crystalline" compound left over from the discontinued project while spring-cleaning in the lab. This compound, later named chlordiazepoxide, had not been tested in 1955 because of Sternbach's focus on other issues. Expecting pharmacology results to be negative, and hoping to publish the chemistry-related findings, researchers submitted it for a standard battery of animal tests. However, the compound showed very strong sedative, anticonvulsant, and muscle relaxant effects. These impressive clinical findings led to its speedy introduction throughout the world in 1960 under the brand name Librium.[180][181] Following chlordiazepoxide, diazepam marketed by Hoffmann–La Roche under the brand name Valium in 1963, and for a while the two were the most commercially successful drugs. The introduction of benzodiazepines led to a decrease in the prescription of barbiturates, and by the 1970s they had largely replaced the older drugs for sedative and hypnotic uses.[1]
The new group of drugs was initially greeted with optimism by the medical profession, but gradually concerns arose; in particular, the risk of dependence became evident in the 1980s. Benzodiazepines have a unique history in that they were responsible for the largest-ever class-action lawsuit against drug manufacturers in the United Kingdom, involving 14,000 patients and 1,800 law firms that alleged the manufacturers knew of the dependence potential but intentionally withheld this information from doctors. At the same time, 117 general practitioners and 50 health authorities were sued by patients to recover damages for the harmful effects of dependence and withdrawal. This led some doctors to require a signed consent form from their patients and to recommend that all patients be adequately warned of the risks of dependence and withdrawal before starting treatment with benzodiazepines.[182] The court case against the drug manufacturers never reached a verdict; legal aid had been withdrawn and there were allegations that the consultant psychiatrists, the expert witnesses, had a conflict of interest. This litigation led to changes in the British law, making class action lawsuits more difficult.[183]
Although antidepressants with anxiolytic properties have been introduced, and there is increasing awareness of the adverse effects of benzodiazepines, prescriptions for short-term anxiety relief have not significantly dropped.[9] For treatment of insomnia, benzodiazepines are now less popular than nonbenzodiazepines, which include zolpidem, zaleplon and eszopiclone.[184] Nonbenzodiazepines are molecularly distinct, but nonetheless, they work on the same benzodiazepine receptors and produce similar sedative effects.[185]
Society and culture[edit]
Legal status[edit]
In the United States, benzodiazepines are Schedule IV drugs under the Federal Controlled Substances Act, even when not on the market (for example, nitrazepam and bromazepam). Flunitrazepam is subject to more stringent regulations in certain states and temazepam prescriptions require specially coded pads in certain states.
In Canada, possession of benzodiazepines is legal for personal use. All benzodiazepines are categorized as Schedule IV substances under the Controlled Drugs and Substances Act.[186] Since 2000, benzodiazepines have been classed as targeted substances, meaning that additional regulations exist especially affecting pharmacists' records.[187] Since approximately 2014, Health Canada, the Canadian Medical Association and provincial Colleges of Physicians and Surgeons have been issuing progressively stricter guidelines for the prescription of benzodiazepines, especially for the elderly (e.g. College of Physicians and Surgeons of British Columbia).[188] Unfortunately, many of these guidelines are not readily available to the public.[189]
In the United Kingdom, the benzodiazepines are schedule 4 controlled drugs, except for flunitrazepam, temazepam and midazolam, which are schedule 3 controlled drugs and carry stronger penalties for possession and trafficking.[190][191]
In the Netherlands, since October 1993, benzodiazepines, including formulations containing less than 20 mg of temazepam, are all placed on List 2 of the Opium Law. A prescription is needed for possession of all benzodiazepines. Temazepam formulations containing 20 mg or greater of the drug are placed on List 1, thus requiring doctors to write prescriptions in the List 1 format.[192]
In East Asia and Southeast Asia, temazepam and nimetazepam are often heavily controlled and restricted. In certain countries, triazolam, flunitrazepam, flutoprazepam and midazolam are also restricted or controlled to certain degrees. In Hong Kong, all benzodiazepines are regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance.[193] Previously only brotizolam, flunitrazepam and triazolam were classed as dangerous drugs.[194]
Internationally, benzodiazepines are categorized as Schedule IV controlled drugs, apart from flunitrazepam, which is a Schedule III drug under the Convention on Psychotropic Substances.[195]
Recreational use[edit]
Xanax (alprazolam) 2 mg tri-score tablets
Main articles: Benzodiazepine drug misuse and Drug-related crime
Benzodiazepines are considered major drugs of abuse.[20] Benzodiazepine abuse is mostly limited to individuals who abuse other drugs, i.e., poly-drug abusers. On the international scene, benzodiazepines are categorized as Schedule IV controlled drugs by the INCB, apart from flunitrazepam, which is a Schedule III drug under the Convention on Psychotropic Substances.[196] Some variation in drug scheduling exists in individual countries; for example, in the United Kingdom, midazolam and temazepam are Schedule III controlled drugs.
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. (August 2016)
British law requires that temazepam (but not midazolam) be stored in safe custody. Safe custody requirements ensures that pharmacists and doctors holding stock of temazepam must store it in securely fixed double-locked steel safety cabinets and maintain a written register, which must be bound and contain separate entries for temazepam and must be written in ink with no use of correction fluid (although a written register is not required for temazepam in the United Kingdom). Disposal of expired stock must be witnessed by a designated inspector (either a local drug-enforcement police officer or official from health authority).[197][198] Benzodiazepine abuse ranges from occasional binges on large doses, to chronic and compulsive drug abuse of high doses.[199]
Benzodiazepines are used recreationally and by problematic drug misusers. Mortality is higher among poly-drug misusers that also use benzodiazepines. Heavy alcohol use also increases mortality among poly-drug users.[18] Dependence and tolerance, often coupled with dosage escalation, to benzodiazepines can develop rapidly among drug misusers; withdrawal syndrome may appear after as little as three weeks of continuous use. Long-term use has the potential to cause both physical and psychological dependence and severe withdrawal symptoms such as depression, anxiety (often to the point of panic attacks), and agoraphobia.[13] Benzodiazepines and, in particular, temazepam are sometimes used intravenously, which, if done incorrectly or in an unsterile manner, can lead to medical complications including abscesses, cellulitis, thrombophlebitis, arterial puncture, deep vein thrombosis, and gangrene. Sharing syringes and needles for this purpose also brings up the possibility of transmission of hepatitis, HIV, and other diseases. Benzodiazepines are also misused intranasally, which may have additional health consequences. Once benzodiazepine dependence has been established, a clinician usually converts the patient to an equivalent dose of diazepam before beginning a gradual reduction program.[200]
A 1999–2005 Australian police survey of detainees reported preliminary findings that self-reported users of benzodiazepines were less likely than non-user detainees to work full-time and more likely to receive government benefits, use methamphetamine or heroin, and be arrested or imprisoned.[201] Benzodiazepines are sometimes used for criminal purposes; they serve to incapacitate a victim in cases of drug assisted rape or robbery.[202]
Overall, anecdotal evidence suggests that temazepam may be the most psychologically habit-forming (addictive) benzodiazepine. Temazepam abuse reached epidemic proportions in some parts of the world, in particular, in Europe and Australia, and is a major drug of abuse in many Southeast Asian countries. This led authorities of various countries to place temazepam under a more restrictive legal status. Some countries, such as Sweden, banned the drug outright.[203] Temazepam also has certain pharmacokinetic properties of absorption, distribution, elimination, and clearance that make it more apt to abuse compared to many other benzodiazepines.[204][205]
Veterinary use[edit]
Benzodiazepines are used in veterinary practice in the treatment of various disorders and conditions. As in humans, they are used in the first-line management of seizures, status epilepticus, and tetanus, and as maintenance therapy in epilepsy (in particular, in cats).[206][207][208] They are widely used in small and large animals (including horses, swine, cattle and exotic and wild animals) for their anxiolytic and sedative effects, as pre-medication before surgery, for induction of anesthesia and as adjuncts to anesthesia.[206][209]
References[edit]
^ Jump up to: a b Shorter E (2005). "Benzodiazepines". A Historical Dictionary of Psychiatry. Oxford University Press. pp. 41–2. ISBN 0-19-517668-5.
Jump up ^ Treating Alcohol and Drug Problems in Psychotherapy Practice Doing What Works. New York: Guilford Publications. 2011. p. 47. ISBN 9781462504381.
Jump up ^ Goldberg, Raymond (2009). Drugs Across the Spectrum. Cengage Learning. p. 195. ISBN 9781111782009.
^ Jump up to: a b Page C, Michael C, Sutter M, Walker M, Hoffman BB (2002). Integrated Pharmacology (2nd ed.). C.V. Mosby. ISBN 978-0-7234-3221-0.
^ Jump up to: a b Olkkola KT, Ahonen J (2008). "Midazolam and other benzodiazepines". In Schüttler J, Schwilden H. Modern Anesthetics. Handbook of Experimental Pharmacology. 182. pp. 335–60. doi:10.1007/978-3-540-74806-9_16. ISBN 978-3-540-72813-9. PMID 18175099.
^ Jump up to: a b Dikeos DG, Theleritis CG, Soldatos CR (2008). "Benzodiazepines: effects on sleep". In Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ. Sleep Disorders: Diagnosis and Therapeutics. Informa Healthcare. pp. 220–2. ISBN 0-415-43818-7.
^ Jump up to: a b Saïas T, Gallarda T (September 2008). "[Paradoxical aggressive reactions to benzodiazepine use: a review]". L'Encéphale (in French). 34 (4): 330–6. doi:10.1016/j.encep.2007.05.005. PMID 18922233.
^ Jump up to: a b Dodds TJ (March 2017). "Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature". The Primary Care Companion for CNS Disorders. 19 (2). doi:10.4088/PCC.16r02037. PMID 28257172.
^ Jump up to: a b Lader M (2008). "Effectiveness of benzodiazepines: do they work or not?". Expert Review of Neurotherapeutics (PDF). 8 (8): 1189–91. doi:10.1586/14737175.8.8.1189. PMID 18671662.
^ Jump up to: a b c d Lader M, Tylee A, Donoghue J (2009). "Withdrawing benzodiazepines in primary care". CNS Drugs. 23 (1): 19–34. doi:10.2165/0023210-200923010-00002. PMID 19062773.
^ Jump up to: a b c d e f g h i Ashton H (May 2005). "The diagnosis and management of benzodiazepine dependence" (PDF). Current Opinion in Psychiatry. 18 (3): 249–55. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148.
^ Jump up to: a b c Ashton H (2004). "Benzodiazepine dependence". In Haddad P, Dursun S, Deakin B. Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. Oxford University Press. pp. 239–60. ISBN 978-0-19-852748-0.
^ Jump up to: a b c McIntosh A, Semple D, Smyth R, Burns J, Darjee R (2005). "Depressants". Oxford Handbook of Psychiatry (1st ed.). Oxford University Press. p. 540. ISBN 0-19-852783-7.
Jump up ^ By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015). "American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". Journal of the American Geriatrics Society. 63 (11): 2227–46. doi:10.1111/jgs.13702. PMID 26446832.
^ Jump up to: a b c American College of Obstetricians and Gynecologists Committee on Practice Bulletins—Obstetrics (April 2008). "ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation". Obstetrics and Gynecology. 111 (4): 1001–20. doi:10.1097/AOG.0b013e31816fd910. PMID 18378767. Lay summary. CS1 maint: Uses authors parameter (link)
^ Jump up to: a b Fraser AD (October 1998). "Use and abuse of the benzodiazepines". Therapeutic Drug Monitoring. 20 (5): 481–9. doi:10.1097/00007691-199810000-00007. PMC 2536139  . PMID 9780123.
Jump up ^ "FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use". FDA. August 31, 2016. Retrieved 1 September 2016.
^ Jump up to: a b c Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M (2009). "A systematic review of research examining benzodiazepine-related mortality". Pharmacoepidemiology and Drug Safety. 18 (2): 93–103. doi:10.1002/pds.1694. PMID 19125401.
^ Jump up to: a b White JM, Irvine RJ (July 1999). "Mechanisms of fatal opioid overdose". Addiction. 94 (7): 961–72. doi:10.1046/j.1360-0443.1999.9479612.x. PMID 10707430.
^ Jump up to: a b Lader MH (1999). "Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?". European Neuropsychopharmacology. 9 (Suppl 6): S399–405. doi:10.1016/S0924-977X(99)00051-6. PMID 10622686.
^ Jump up to: a b c d e f g h Royal Pharmaceutical Society of Great Britain (2009). British National Formulary (BNF 57). BMJ Group and RPS Publishing. ISBN 978-0-85369-845-6.
^ Jump up to: a b Perugi G, Frare F, Toni C (2007). "Diagnosis and treatment of agoraphobia with panic disorder". CNS Drugs. 21 (9): 741–64. doi:10.2165/00023210-200721090-00004. PMID 17696574.
Jump up ^ Tesar GE (May 1990). "High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience". The Journal of Clinical Psychiatry. 51 Suppl (Suppl): 4–10; discussion 50–3. PMID 1970816.
Jump up ^ Faught E (2004). "Treatment of refractory primary generalized epilepsy". Reviews in Neurological Diseases. 1 Suppl 1 (Suppl 1): S34–43. PMID 16400293.
Jump up ^ Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP (August 2003). "WCA recommendations for the long-term treatment of generalized anxiety disorder". CNS Spectrums. 8 (8 Suppl 1): 53–61. PMID 14767398.
Jump up ^ "Benzodiazepines in chronic pain". February 2016. Retrieved 2016-09-22.
Jump up ^ Stevens JC, Pollack MH (2005). "Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents". The Journal of Clinical Psychiatry. 66 (Suppl 2): 21–7. PMID 15762816. The frequent use of benzodiazepines for the treatment of anxiety is likely a reflection of their effectiveness, rapid onset of anxiolytic effect, and tolerability.
^ Jump up to: a b c d e f McIntosh A, Cohen A, Turnbull N, et al. (2004). "Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder" (PDF). National Collaborating Centre for Primary Care. Retrieved 2009-06-16.
Jump up ^ Bandelow B, Zohar J, Hollander E, Kasper S & Möller HJ (October 2002). "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders". The World Journal of Biological Psychiatry. Informa Healthcare. 3 (4): 171–99. doi:10.3109/15622970209150621. PMID 12516310.
^ Jump up to: a b c Work Group on Panic Disorder (January 2009). "APA Practice Guideline for the Treatment of Patients With Panic Disorder, Second Edition" (PDF). Retrieved July 12, 2009.
Jump up ^ Barbui C, Cipriani A (2009). "Proposal for the inclusion in the WHO Model List of Essential Medicines of a selective serotonin-reuptake inhibitor for Generalised Anxiety Disorder" (PDF). WHO Collaborating Centre for Research and Training in Mental Health. Retrieved 2009-06-23.
Jump up ^ Cloos JM, Ferreira V (January 2009). "Current use of benzodiazepines in anxiety disorders". Current Opinion in Psychiatry. 22 (1): 90–5. doi:10.1097/YCO.0b013e32831a473d. PMID 19122540.
Jump up ^ Martin JL, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C (September 2007). "Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials". Journal of Psychopharmacology. 21 (7): 774–82. doi:10.1177/0269881107077355. PMID 17881433.
Jump up ^ "Clinical Guideline 22 (amended). Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care" (PDF). National Institute for Health and Clinical Excellence. 2007. pp. 23–25. Retrieved 2009-08-08.
Jump up ^ Canadian Psychiatric Association (July 2006). "Clinical practice guidelines. Management of anxiety disorders". The Canadian Journal of Psychiatry (PDF). 51 (8 Suppl 2): 9S–91S. PMID 16933543.
^ Jump up to: a b Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D (July 2015). "Efficacy of treatments for anxiety disorders: a meta-analysis". International Clinical Psychopharmacology. 30 (4): 183–92. doi:10.1097/YIC.0000000000000078. PMID 25932596.
^ Jump up to: a b c d "Technology Appraisal Guidance 77. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia" (PDF). National Institute for Clinical Excellence. April 2004. Archived from the original (PDF) on 2008-12-03. Retrieved 2009-07-26.
^ Jump up to: a b c Ramakrishnan K, Scheid DC (August 2007). "Treatment options for insomnia". American Family Physician. 76 (4): 517–26. PMID 17853625.
Jump up ^ Carlstedt RA (13 December 2009). Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research. Springer Publishing Company. pp. 128–30. ISBN 0-8261-1094-0.
^ Jump up to: a b c Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M (June 2005). "Manifestations and Management of Chronic Insomnia in Adults. Summary, Evidence Report/Technology Assessment: Number 125" (PDF). Agency for Healthcare Research and Quality.
Jump up ^ Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R (June 2016). "Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010". Pharmacoepidemiology and Drug Safety. 25 (6): 637–45. doi:10.1002/pds.3951. PMC 4889508  . PMID 26711081.
Jump up ^ "Approval letter for Ambien" (PDF). Food and Drug Administration.
^ Jump up to: a b American Geriatrics Society. "Five Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation. American Geriatrics Society. Retrieved August 1, 2013 , which cites
Finkle WD, Der JS, Greenland S, Adams JL, Ridgeway G, Blaschke T, Wang Z, Dell RM, VanRiper KB (October 2011). "Risk of Fractures Requiring Hospitalization After an Initial Prescription for Zolpidem, Alprazolam, Lorazepam, or Diazepam in Older Adult". Journal of the American Geriatrics Society. 59 (10): 1883–90. doi:10.1111/j.1532-5415.2011.03591.x. PMID 22091502.
Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A (2005). "Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review". Drugs & Aging. 22 (9): 749–65. doi:10.2165/00002512-200522090-00004. PMID 16156679.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677  . PMID 22376048.
Jump up ^ Scottish Intercollegiate Guidelines Network (2005). "Diagnosis and management of epilepsy in adults" (PDF). pp. 17–9. Retrieved 2009-06-05.
^ Jump up to: a b Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R (October 2004). Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care (PDF). London: Royal College of General Practitioners. pp. 61, 64–65. Retrieved 2009-06-02.
^ Jump up to: a b c Shorvon SD (March 2009). "Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009". Epilepsia. 50 Suppl 3 (Suppl 3): 93–130. doi:10.1111/j.1528-1167.2009.02042.x. PMID 19298435.
Jump up ^ Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R (October 2004). "Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care (Appendix B)" (PDF). London: Royal College of General Practitioners. p. 432. Retrieved 2009-06-02.
Jump up ^ Ashworth M, Gerada C (August 1997). "ABC of mental health. Addiction and dependence--II: Alcohol". BMJ. 315 (7104): 358–60. doi:10.1136/bmj.315.7104.358. PMC 2127236  . PMID 9270461.
Jump up ^ Kraemer KL, Conigliaro J, Saitz R (June 1999). "Managing alcohol withdrawal in the elderly". Drugs & Aging. 14 (6): 409–25. doi:10.2165/00002512-199914060-00002. PMID 10408740.
Jump up ^ Prater CD, Miller KE, Zylstra RG (September 1999). "Outpatient detoxification of the addicted or alcoholic patient". American Family Physician. 60 (4): 1175–83. PMID 10507746.
Jump up ^ Ebell MH (April 2006). "Benzodiazepines for alcohol withdrawal". American Family Physician. 73 (7): 1191. PMID 16623205.
Jump up ^ Peppers MP (1996). "Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease". Pharmacotherapy. 16 (1): 49–57. doi:10.1002/j.1875-9114.1996.tb02915.x (inactive 2017-01-30). PMID 8700792.
Jump up ^ Devlin JW, Roberts RJ (July 2009). "Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids". Critical Care Clinics. 25 (3): 431–49, vii. doi:10.1016/j.ccc.2009.03.003. PMID 19576523.
Jump up ^ Broscheit J, Kranke P (February 2008). "[The preoperative medication: background and specific indications for the selection of the drugs]". Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 43 (2): 134–43. doi:10.1055/s-2008-1060547. PMID 18293248.
Jump up ^ Berthold C (May 2007). "Enteral sedation: safety, efficacy, and controversy". Compendium of Continuing Education in Dentistry. 28 (5): 264–71; quiz 272, 282. PMID 17607891.
Jump up ^ Mañon-Espaillat R, Mandel S (January 1999). "Diagnostic algorithms for neuromuscular diseases". Clinics in Podiatric Medicine and Surgery. 16 (1): 67–79. PMID 9929772.
Jump up ^ Kamen L, Henney HR, Runyan JD (February 2008). "A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury". Current Medical Research and Opinion. 24 (2): 425–39. doi:10.1185/030079908X261113. PMID 18167175.
Jump up ^ Wyatt JP, Illingworth RN, Robertson CE, Clancy MJ, Munro PT (2005). "Poisoning". Oxford Handbook of Accident and Emergency Medicine (2nd ed.). Oxford University Press. pp. 173–208. ISBN 978-0-19-852623-0.
Jump up ^ Zimbroff DL (2008). "Pharmacological control of acute agitation: focus on intramuscular preparations". CNS Drugs. 22 (3): 199–212. doi:10.2165/00023210-200822030-00002. PMID 18278976.
Jump up ^ Curtin F, Schulz P (March 2004). "Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis". Journal of Affective Disorders. 78 (3): 201–8. doi:10.1016/S0165-0327(02)00317-8. PMID 15013244.
Jump up ^ Gillies D, Sampson S, Beck A, Rathbone J (April 2013). "Benzodiazepines for psychosis-induced aggression or agitation". Cochrane Database of Systematic Reviews (4): CD003079. doi:10.1002/14651858.CD003079.pub3. PMID 23633309.
Jump up ^ Schenck CH, Arnulf I, Mahowald MW (June 2007). "Sleep and sex: what can go wrong? A review of the literature on sleep related disorders and abnormal sexual behaviors and experiences". Sleep. 30 (6): 683–702. PMC 1978350  . PMID 17580590.
Jump up ^ Ferini-Strambi L, Zucconi M (September 2000). "REM sleep behavior disorder". Clinical Neurophysiology. 111 Suppl 2: S136–40. doi:10.1016/S1388-2457(00)00414-4. PMID 10996567.
Jump up ^ Silber MH (February 2001). "Sleep disorders". Neurologic Clinics. 19 (1): 173–86. doi:10.1016/S0733-8619(05)70011-6. PMID 11471763.
Jump up ^ Grupo Brasileiro de Estudos em Síndrome das Pernas Inquietas (GBE-SPI) (September 2007). "Síndrome das pernas inquietas: diagnóstico e tratamento. Opinião de especialistas brasileiros" [Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts]. Arquivos de Neuro-Psiquiatria (in Portuguese). 65 (3A): 721–7. doi:10.1590/S0004-282X2007000400035. PMID 17876423.
Jump up ^ Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C (December 2008). "Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice" (PDF). Movement Disorders. 23 (16): 2267–302. doi:10.1002/mds.22254. PMID 18925578.
Jump up ^ Schatzberg AF, Nemeroff CB, eds. (May 6, 2009). The American Psychiatric Publishing Textbook of Psychopharmacology (Fourth ed.). American Psychiatric Publishing. p. 470. ISBN 978-1-58562-309-9.
Jump up ^ Bandelow B (September 2008). "The medical treatment of obsessive-compulsive disorder and anxiety". CNS Spectrums. 13 (9 Suppl 14): 37–46. PMID 18849910.
Jump up ^ Attard A, Ranjith G, Taylor D (August 2008). "Delirium and its treatment". CNS Drugs. 22 (8): 631–44. doi:10.2165/00023210-200822080-00002. PMID 18601302.
Jump up ^ Gallegos J, Vaidya P, D'Agati D, Jayaram G, Nguyen T, Tripathi A, Trivedi JK, Reti IM (June 2012). "Decreasing adverse outcomes of unmodified electroconvulsive therapy: suggestions and possibilities". The Journal of ECT. 28 (2): 77–81. doi:10.1097/YCT.0b013e3182359314. PMID 22531198.
^ Jump up to: a b c d e Ballenger JC (2000). "Benzodiazepine receptors agonists and antagonists". In Sadock VA, Sadock BJ, Kaplan HI. Kaplan & Sadock's Comprehensive Textbook of Psychiatry (7th ed.). Lippincott Williams & Wilkins. pp. 2317–23. ISBN 0-683-30128-4.
^ Jump up to: a b c d Meyler L, Aronson JK, eds. (2006). Meyler's Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions (15th ed.). Elsevier. pp. 429–43. ISBN 0-444-50998-4.
Jump up ^ Committee on Safety of Medicines (1988). "Benzodiazepines, dependence and withdrawal symptoms" (PDF). Medicines and Healthcare products Regulatory Agency. Retrieved 2009-05-28.
^ Jump up to: a b c d Moody D (2004). "Drug interactions with benzodiazepines". In Raymon LP, Mozayani A. Handbook of Drug Interactions: a Clinical and Forensic Guide. Humana. pp. 3–88. ISBN 1-58829-211-8.
Jump up ^ Roach SS, Ford SM (2006). "Sedatives and hypnotics". Introductory Clinical Pharmacology (8th ed.). Lippincott Williams & Wilkins. p. 236. ISBN 978-0-7817-7595-3.
Jump up ^ Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR (September 1998). "Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies" (PDF). BMJ. 317 (7162): 839–43. doi:10.1136/bmj.317.7162.839. PMC 31092  . PMID 9748174.
Jump up ^ American Academy of Pediatrics Committee on Drugs (June 1998). "Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs" (PDF). Pediatrics. 101 (6): 1079–88. PMID 9614425.
Jump up ^ Temazepam-Rxlist Pregnancy Category@
Jump up ^ Iqbal MM, Sobhan T, Ryals T (January 2002). "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant" (PDF). Psychiatric Services. 53 (1): 39–49. doi:10.1176/appi.ps.53.1.39. PMID 11773648.
Jump up ^ Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clinics in Geriatric Medicine. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.
Jump up ^ Bain KT (June 2006). "Management of chronic insomnia in elderly persons". The American Journal of Geriatric Pharmacotherapy. 4 (2): 168–92. doi:10.1016/j.amjopharm.2006.06.006. PMID 16860264.
Jump up ^ Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A (2005). "Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review". Drugs & Aging. 22 (9): 749–65. doi:10.2165/00002512-200522090-00004. PMID 16156679.
Jump up ^ Khong TP, de Vries F, Goldenberg JS, Klungel OH, Robinson NJ, Ibáñez L, Petri H (July 2012). "Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States". Calcified Tissue International. 91 (1): 24–31. doi:10.1007/s00223-012-9603-8. PMC 3382650  . PMID 22566242.
Jump up ^ Bogunovic OJ, Greenfield SF (March 2004). "Practical geriatrics: Use of benzodiazepines among elderly patients" (PDF). Psychiatric Services. 55 (3): 233–5. doi:10.1176/appi.ps.55.3.233. PMID 15001721.
^ Jump up to: a b Jackson SG, Jansen P, Mangoni A (22 May 2009). Prescribing for Elderly Patients. Wiley. pp. 47–48. ISBN 0-470-02428-3.
Jump up ^ Rosenthal TC, Williams M, Naughton BJ (2006). Office care geriatrics. Philadelphia: Lippincott Williams Wilkins. pp. 260–262. ISBN 0-7817-6196-4.
Jump up ^ Hulse GK, Lautenschlager NT, Tait RJ, Almeida OP (2005). "Dementia associated with alcohol and other drug use". International Psychogeriatrics. 17 Suppl 1 (Suppl 1): S109–27. doi:10.1017/S1041610205001985. PMID 16240487.
Jump up ^ Verdoux H, Lagnaoui R, Begaud B (March 2005). "Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies". Psychological Medicine. 35 (3): 307–15. doi:10.1017/S0033291704003897. PMID 15841867.
Jump up ^ Snowden M, Sato K, Roy-Byrne P (September 2003). "Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature". Journal of the American Geriatrics Society. 51 (9): 1305–17. doi:10.1046/j.1532-5415.2003.51417.x. PMID 12919245.
Jump up ^ Wang PS, Brookhart MA, Setoguchi S, Patrick AR, Schneeweiss S (November 2006). "Psychotropic medication use for behavioral symptoms of dementia". Current Neurology and Neuroscience Reports. 6 (6): 490–5. doi:10.1007/s11910-006-0051-6. PMID 17074284.
^ Jump up to: a b Longo LP, Johnson B (April 2000). "Addiction: Part I. Benzodiazepines—side effects, abuse risk and alternatives". American Family Physician. 61 (7): 2121–8. PMID 10779253.
Jump up ^ Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". The Lancet. 369 (9566): 1047–53. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831.
^ Jump up to: a b Tasman A, Lieberman JA (2006). Handbook of Psychiatric Drugs. Wiley. p. 151. ISBN 0-470-02821-1.
Jump up ^ Stone KL, Ensrud KE, Ancoli-Israel S (September 2008). "Sleep, insomnia and falls in elderly patients". Sleep Medicine. 9 Suppl 1: S18–22. doi:10.1016/S1389-9457(08)70012-1. PMID 18929314.
Jump up ^ Rapoport MJ, Lanctôt KL, Streiner DL, Bédard M, Vingilis E, Murray B, Schaffer A, Shulman KI, Herrmann N (May 2009). "Benzodiazepine use and driving: a meta-analysis". The Journal of Clinical Psychiatry. 70 (5): 663–73. doi:10.4088/JCP.08m04325. PMID 19389334.
Jump up ^ Orriols L, Salmi LR, Philip P, Moore N, Delorme B, Castot A, Lagarde E (August 2009). "The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies". Pharmacoepidemiology and Drug Safety. 18 (8): 647–58. doi:10.1002/pds.1763. PMC 2780583  . PMID 19418468.
Jump up ^ "benzodiazepines-oral" at medicinenet.com
Jump up ^ Hammersley D, Beeley L (1996). "The effects of medication on counselling". In Palmer S, Dainow S, Milner P. Counselling: The BACP Counselling Reader. 1. Sage. pp. 211–4. ISBN 978-0-8039-7477-7.
^ Jump up to: a b c Stewart SA (2005). "The effects of benzodiazepines on cognition" (PDF). The Journal of Clinical Psychiatry. 66 Suppl 2 (Suppl 2): 9–13. PMID 15762814.
^ Jump up to: a b Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004). "Cognitive effects of long-term benzodiazepine use: a meta-analysis". CNS Drugs. 18 (1): 37–48. doi:10.2165/00023210-200418010-00004. PMID 14731058.
Jump up ^ Riss J, Cloyd J, Gates J, Collins S (August 2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics". Acta Neurologica Scandinavica. 118 (2): 69–86. doi:10.1111/j.1600-0404.2008.01004.x. PMID 18384456.
^ Jump up to: a b Paton C (2002). "Benzodiazepines and disinhibition: a review" (PDF). The Psychiatrist. 26 (12): 460–2. doi:10.1192/pb.26.12.460.
Jump up ^ Bond AJ (1998). "Drug-induced behavioural disinhibition: incidence, mechanisms and therapeutic implications". CNS Drugs. 9 (1): 41–57. doi:10.2165/00023210-199809010-00005.
Jump up ^ Drummer OH (February 2002). "Benzodiazepines - Effects on Human Performance and Behavior". Forensic Science Review. 14 (1–2): 1–14. PMID 26256485.
^ Jump up to: a b Ashton H (2007). "Drug dependency: benzodiazepines". In Ayers S, Baum A, McManus C, Newman S. Cambridge Handbook of Psychology, Health and Medicine (2nd ed.). Cambridge University Press. pp. 675–8. ISBN 978-0-521-87997-2.
^ Jump up to: a b c d e f g Michelini S, Cassano GB, Frare F, et al. (1996). "Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders". Pharmacopsychiatry. 29: 127–134. doi:10.1055/s-2007-979558.
^ Jump up to: a b Lydiard RB, Brawman-Mintzer O, Ballenger JC (August 1996). "Recent developments in the psychopharmacology of anxiety disorders". Journal of Consulting and Clinical Psychology. 64 (4): 660–8. doi:10.1037/0022-006x.64.4.660. PMID 8803355.
^ Jump up to: a b Tasman A, Kay J, Lieberman JA, eds. (2008). Psychiatry (3rd ed.). Chichester, England: John Wiley & Sons. pp. 1186–1200, 2603–2615. ISBN 978-0470065716.
Jump up ^ Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY (September 1996). "Treatment of recent trauma survivors with benzodiazepines: a prospective study". The Journal of Clinical Psychiatry. 57 (9): 390–4. PMID 9746445.
Jump up ^ Rosen CS, Greenbaum MA, Schnurr PP, Holmes TH, Brennan PL, Friedman MJ (December 2013). "Do benzodiazepines reduce the effectiveness of exposure therapy for posttraumatic stress disorder?". The Journal of Clinical Psychiatry. 74 (12): 1241–8. doi:10.4088/JCP.13m08592. PMID 24434093.
Jump up ^ Wilhelm FH, Roth WT (September 1997). "Acute and delayed effects of alprazolam on flight phobics during exposure". Behaviour Research and Therapy. 35 (9): 831–41. doi:10.1016/s0005-7967(97)00033-8. PMID 9299803.
Jump up ^ Matar MA, Zohar J, Kaplan Z, Cohen H (April 2009). "Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD". European Neuropsychopharmacology. 19 (4): 283–95. doi:10.1016/j.euroneuro.2008.12.004. PMID 19167197.
Jump up ^ Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S (October 2003). "Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life". Psychological Medicine. 33 (7): 1223–37. doi:10.1017/s0033291703008213. PMID 14580077.
Jump up ^ Pary R, Lewis S (2008). "Prescribing benzodiazepines in clinical practice". Resident and Staff Physician. 54 (1): 8–17.
Jump up ^ Nardi AE, Perna G (May 2006). "Clonazepam in the treatment of psychiatric disorders: an update". International Clinical Psychopharmacology. 21 (3): 131–42. doi:10.1097/01.yic.0000194379.65460.a6. PMID 16528135.
Jump up ^ Otto MW, Bruce SE, Deckersbach T (2005). "Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need" (PDF). The Journal of Clinical Psychiatry. 66 Suppl 2 (Suppl 2): 34–8. PMID 15762818.
^ Jump up to: a b c Chouinard G (2004). "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound" (PDF). The Journal of Clinical Psychiatry. 65 Suppl 5 (Suppl 5): 7–12. PMID 15078112.
Jump up ^ Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S (October 2003). "Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life". Psychological Medicine. 33 (7): 1223–37. doi:10.1017/s0033291703008213. PMID 14580077.
Jump up ^ Holbrook AM (2004). "Treating insomnia". BMJ. 329 (7476): 1198–9. doi:10.1136/bmj.329.7476.1198. PMC 529353  . PMID 15550406.
Jump up ^ Poyares D, Guilleminault C, Ohayon MM, Tufik S (2004-06-01). "Chronic benzodiazepine usage and withdrawal in insomnia patients". Journal of Psychiatric Research. 38 (3): 327–34. doi:10.1016/j.jpsychires.2003.10.003. PMID 15003439.
Jump up ^ Friedman MJ (1998). "Pharmacotherapy for posttraumatic stress disorder: a status report". Psychiatry and Clinical Neurosciences. 52: S115–S121. doi:10.1046/j.1440-1819.1998.0520s5S115.x.
Jump up ^ Heather N, Bowie A, Ashton H, McAvoy B, Spencer I, Brodie J, Giddings D (2004). "Randomised controlled trial of two brief interventions against long-term benzodiazepine use: outcome of intervention". Addiction Research & Theory. 12 (2): 141–154. doi:10.1080/1606635310001634528.
Jump up ^ Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, Zohar J, et al. (2008-01-01). "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision". The World Journal of Biological Psychiatry. 9 (4): 248–312. doi:10.1080/15622970802465807. PMID 18949648.
Jump up ^ Ashton H (May 2005). "The diagnosis and management of benzodiazepine dependence". Current Opinion in Psychiatry. 18 (3): 249–55. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148.
Jump up ^ Morin CM, Bélanger L, Bastien C, Vallières A (January 2005). "Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse". Behaviour Research and Therapy. 43 (1): 1–14. doi:10.1016/j.brat.2003.12.002. PMID 15531349.
^ Jump up to: a b American Psychiatry Association (2013). Diagnostic and statistical manual of mental disorders : DSM-5 (5th ed.). Washington: American Psychiatric Publishing. ISBN 978-0-89042-555-8.
Jump up ^ Harrison PC, Gelder MG, Cowen P (2006). "The misuse of alcohol and drugs". Shorter Oxford Textbook of Psychiatry (5th ed.). Oxford University Press. pp. 461–2. ISBN 0-19-856667-0.
Jump up ^ Collier J, Longmore M, Amarakone K (31 January 2013). "Psychiatry". Oxford Handbook of Clinical Specialties. OUP Oxford. p. 368. ISBN 978-0-19-150476-1.
Jump up ^ Ashton H (1991). "Protracted withdrawal syndromes from benzodiazepines". Journal of Substance Abuse Treatment. 8 (1–2): 19–28. doi:10.1016/0740-5472(91)90023-4. PMID 1675688.
^ Jump up to: a b c d Ashton CH (2002). Benzodiazepines: how they work & how to withdraw (aka The Ashton Manual). Retrieved 2009-05-27.
Jump up ^ Lal R, Gupta S, Rao R, Kattimani S (2007). "Emergency management of substance overdose and withdrawal" (PDF). Substance Use Disorder. World Health Organization (WHO). p. 82. Retrieved 2009-06-06. Generally, a longer-acting benzodiazepine such as chlordiazepoxide or diazepam is used and the initial dose titrated downward
Jump up ^ Ford C, Law F (July 2014). "Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice" (PDF). smmgp.org.uk.
Jump up ^ Ebadi M (23 October 2007). "Alphabetical presentation of drugs". Desk Reference for Clinical Pharmacology (2nd ed.). USA: CRC Press. p. 512. ISBN 978-1-4200-4743-1.
Jump up ^ Brandt J, Leong C (December 2017). "Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research". Drugs in R&D. 17 (4): 493–507. doi:10.1007/s40268-017-0207-7. PMID 28865038.
Jump up ^ Zhong G, Wang Y, Zhang Y, Zhao Y (2015-05-27). "Association between Benzodiazepine Use and Dementia: A Meta-Analysis". PLOS One. 10 (5): e0127836. doi:10.1371/journal.pone.0127836. PMID 26016483.
Jump up ^ Barbui C, Gastaldon C, Cipriani A (December 2013). "Benzodiazepines and risk of dementia: true association or reverse causation?". Epidemiology and Psychiatric Sciences. 22 (4): 307–8. doi:10.1017/s2045796013000358. PMID 23823009.
^ Jump up to: a b Pariente A, de Gage SB, Moore N, Bégaud B (January 2016). "The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge". CNS Drugs. 30 (1): 1–7. doi:10.1007/s40263-015-0305-4. PMID 26715389.
Jump up ^ Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR (November 2016). "The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a survival analysis using UK Primary Care data". Pharmacoepidemiology and Drug Safety. 25 (11): 1263–1273. doi:10.1002/pds.4028. PMID 27215827.
Jump up ^ Obiora E, Hubbard R, Sanders RD, Myles PR (February 2013). "The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort". Thorax. 68 (2): 163–70. doi:10.1136/thoraxjnl-2012-202374. PMID 23220867.
Jump up ^ Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA (October 2011). "Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study". Journal of the American Geriatrics Society. 59 (10): 1899–907. doi:10.1111/j.1532-5415.2011.03586.x. PMID 22091503.
Jump up ^ Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–83. PMC 2725260  . PMID 19968019.
Jump up ^ Sanders RD, Godlee A, Fujimori T, Goulding J, Xin G, Salek-Ardakani S, Snelgrove RJ, Ma D, Maze M, Hussell T (July 2013). "Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice". Critical Care Medicine. 41 (7): 1627–36. doi:10.1097/ccm.0b013e31827c0c8d. PMID 23478657.
Jump up ^ Galdiero F, Bentivoglio C, Nuzzo I, Ianniello R, Capasso C, Mattera S, Nazzaro C, Galdiero M, Romano Carratelli C (November 1995). "Effects of benzodiazepines on immunodeficiency and resistance in mice". Life Sciences. 57 (26): 2413–23. doi:10.1016/0024-3205(95)02199-0. PMID 8847962.
Jump up ^ Kim HB, Myung SK, Park YC, Park B (February 2017). "Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies". International Journal of Cancer. 140 (3): 513–525. doi:10.1002/ijc.30443. PMID 27667780.
Jump up ^ Brambilla G, Carrozzino R, Martelli A (December 2007). "Genotoxicity and carcinogenicity studies of benzodiazepines". Pharmacological Research. 56 (6): 443–58. doi:10.1016/j.phrs.2007.08.006. PMID 17920927.
Jump up ^ Liaw GW, Hung DZ, Chen WK, Lin CL, Lin IC, Kao CH (December 2015). "Relationship Between Acute Benzodiazepine Poisoning and Acute Pancreatitis Risk: A Population-Based Cohort Study". Medicine. 94 (52): e2376. doi:10.1097/md.0000000000002376. PMID 26717383.
Jump up ^ Lai SW, Lai HC, Lin CL, Liao KF (November 2015). "Zopiclone use associated with increased risk of acute pancreatitis: a case-control study in Taiwan". International Journal of Clinical Practice. 69 (11): 1275–80. doi:10.1111/ijcp.12689. PMID 26133234.
^ Jump up to: a b Overdose Death Rates. By National Institute on Drug Abuse (NIDA).
Jump up ^ Gaudreault P, Guay J, Thivierge RL, Verdy I (1991). "Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment". Drug Safety. 6 (4): 247–65. doi:10.2165/00002018-199106040-00003. PMID 1888441.
Jump up ^ Robin Mantooth (28 January 2010). "Toxicity, benzodiazepine". eMedicine. Retrieved 2010-10-02.
^ Jump up to: a b Ramrakha P, Moore K (2004). "Chapter 14: Drug overdoses". Oxford Handbook of Acute Medicine (2nd ed.). Oxford University Press. pp. 791–838 (798). ISBN 0-19-852072-7.
Jump up ^ Klein-Schwartz W, Oderda GM (January 1991). "Poisoning in the elderly. Epidemiological, clinical and management considerations". Drugs & Aging. 1 (1): 67–89. doi:10.2165/00002512-199101010-00008. PMID 1794007.
Jump up ^ Buckley NA, Dawson AH, Whyte IM, O'Connell DL (January 1995). "Relative toxicity of benzodiazepines in overdose". BMJ. 310 (6974): 219–21. doi:10.1136/bmj.310.6974.219. PMC 2548618  . PMID 7866122.
Jump up ^ Serfaty M, Masterton G (September 1993). "Fatal poisonings attributed to benzodiazepines in Britain during the 1980s". British Journal of Psychiatry. 163 (1): 386–93. doi:10.1192/bjp.163.3.386. PMID 8104653.
Jump up ^ Seger DL (2004). "Flumazenil--treatment or toxin". Journal of Toxicology: Clinical Toxicology. 42 (2): 209–16. doi:10.1081/CLT-120030946. PMID 15214628.
Jump up ^ "Treatment of benzodiazepine overdose with flumazenil. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group". Clinical Therapeutics. 14 (6): 978–95. 1992. PMID 1286503.
Jump up ^ Spivey WH (1992). "Flumazenil and seizures: analysis of 43 cases". Clinical Therapeutics. 14 (2): 292–305. PMID 1611650.
Jump up ^ Goldfrank LR (2002). Goldfrank's Toxicologic Emergencies. McGraw-Hill. ISBN 0-07-136001-8.
^ Jump up to: a b Norman TR, Ellen SR, Burrows GD (1997). "Benzodiazepines in anxiety disorders: managing therapeutics and dependence" (PDF). The Medical Journal of Australia. 167 (9): 490–5. PMID 9397065.
^ Jump up to: a b c Olsen RW, Betz H (2006). "GABA and glycine". In Siegel GJ, Albers RW, Brady S, Price DD. Basic Neurochemistry: Molecular, Cellular and Medical Aspects (7th ed.). Elsevier. pp. 291–302. ISBN 0-12-088397-X.
Jump up ^ Rudolph U, Möhler H (February 2006). "GABA-based therapeutic approaches: GABAA receptor subtype functions". Current Opinion in Pharmacology. 6 (1): 18–23. doi:10.1016/j.coph.2005.10.003. PMID 16376150.
Jump up ^ Puri BK, Tyrer P (28 August 1998). "Clinical psychopharmacology". Sciences Basic to Psychiatry (2nd ed.). Churchill Livingstone. pp. 155–156. ISBN 978-0-443-05514-0. Retrieved 11 July 2009.
Jump up ^ Johnston GA (1996). "GABAA receptor pharmacology". Pharmacology & Therapeutics. 69 (3): 173–98. doi:10.1016/0163-7258(95)02043-8. PMID 8783370.
Jump up ^ Wafford KA, Macaulay AJ, Fradley R, O'Meara GF, Reynolds DS, Rosahl TW (June 2004). "Differentiating the role of gamma-aminobutyric acid type A (GABAA) receptor subtypes". Biochemical Society Transactions. 32 (Pt3): 553–6. doi:10.1042/BST0320553. PMID 15157182.
Jump up ^ Hevers W, Lüddens H (August 1998). "The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes". Molecular Neurobiology. 18 (1): 35–86. doi:10.1007/BF02741459. PMID 9824848.
Jump up ^ Arvat E, Giordano R, Grottoli S, Ghigo E (September 2002). "Benzodiazepines and anterior pituitary function". Journal of Endocrinological Investigation. 25 (8): 735–47. doi:10.1007/bf03345110. PMID 12240908.
^ Jump up to: a b Zavala F (September 1997). "Benzodiazepines, anxiety and immunity". Pharmacology & Therapeutics. 75 (3): 199–216. doi:10.1016/S0163-7258(97)00055-7. PMID 9504140.
Jump up ^ Zisterer DM, Williams DC (September 1997). "Peripheral-type benzodiazepine receptors". General Pharmacology. 29 (3): 305–14. doi:10.1016/S0306-3623(96)00473-9. PMID 9378234.
^ Jump up to: a b Narimatsu E, Niiya T, Kawamata M, Namiki A (June 2006). "[The mechanisms of depression by benzodiazepines, barbiturates and propofol of excitatory synaptic transmissions mediated by adenosine neuromodulation]". Masui (in Japanese). 55 (6): 684–91. PMID 16780077.
^ Jump up to: a b c d e f g h i j k l m n O'Brien (2005). "Benzodiazepine Use, Abuse, and Dependence" (PDF). The Journal of Clinical Psychiatry: 66. Retrieved 5 September 2013.
Jump up ^ "Midazolam Injection" (PDF). Medsafe. New Zealand Ministry of Health. 2012-10-26. Archived from the original (PDF) on 2016-02-22. Retrieved 2016-04-06.
Jump up ^ Cardinali D, Monti J (2006). "Chronopharmacology and its implication to the pharmacology of sleep". In Pandi-Perumal S, Monti J. Clinical pharmacology of sleep. Basel: Birkhäuser. pp. 211–3. ISBN 9783764374402.
^ Jump up to: a b Madsen U, Bräuner-Osborne H, Greenwood JR, Johansen TN, Krogsgaard-Larsen P, Liljefors T, Nielsen M, Frølund B (2005). "GABA and Glutamate receptor ligands and their therapeutic potential in CNS disorders". In Gad SC. Drug Discovery Handbook. Hoboken, N.J: Wiley-Interscience/J. Wiley. pp. 797–907. ISBN 0-471-21384-5.
^ Jump up to: a b Panico R, Powell WH, Richer JC, eds. (1993). A Guide to IUPAC Nomenclature of Organic Compounds. IUPAC/Blackwell Science. pp. 40–3. ISBN 0-632-03488-2. ; Moss GP (1998). "Nomenclature of fused and bridged fused ring systems (IUPAC Recommendations 1998)" (PDF). Pure and Applied Chemistry. 70 (1): 143–216. doi:10.1351/pac199870010143.
Jump up ^ CAS registry number:2898-08-0 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; other names: Ro 05-2921, dechlorodemethyldiazepam.
Jump up ^ Ripka WC, De Lucca GV, Bach AC, Pottorf RS, Blaney JM (1993). "Protein β-turn mimetics I. Design, synthesis, and evaluation in model cyclic peptides". Tetrahedron. 49 (17): 3593–3608. doi:10.1016/S0040-4020(01)90217-0.
Jump up ^ Hata M, Marshall GR (2006). "Do benzodiazepines mimic reverse-turn structures?". Journal of Computer-Aided Molecular Design. 20 (5): 321–331. Bibcode:2006JCAMD..20..321H. doi:10.1007/s10822-006-9059-x. PMID 16972167.
^ Jump up to: a b c d e Juergens, MD, Steven M. "Understanding Benzodiazepines" (PDF). California Society of Addiction Medicine. Retrieved 25 April 2012.
^ Jump up to: a b c d e Carlo P, Finollo R, Ledda A, Brambilla G (January 1989). "Absence of liver DNA fragmentation in rats treated with high oral doses of 32 benzodiazepine drugs". Fundamental and Applied Toxicology. 12 (1): 34–41. doi:10.1016/0272-0590(89)90059-6. PMID 2925017.
Jump up ^ Sternbach LH (1979). "The benzodiazepine story". Journal of Medicinal Chemistry. 22 (1): 1–7. doi:10.1021/jm00187a001. PMID 34039. During this cleanup operation, my co-worker, Earl Reeder, drew my attention to a few hundred milligrams of two products, a nicely crystalline base and its hydrochloride. Both the base, which had been prepared by treating the quinazoline N-oxide 11 with methylamine, and its hydrochloride had been made sometime in 1955. The products were not submitted for pharmacological testing at that time because of our involvement with other problems
Jump up ^ Miller NS, Gold MS (1990). "Benzodiazepines: reconsidered". Advances in Alcohol & Substance Abuse. 8 (3–4): 67–84. doi:10.1300/J251v08n03_06. PMID 1971487.
Jump up ^ King MB (1992). "Is there still a role for benzodiazepines in general practice?". British Journal of General Practice. 42 (358): 202–5. PMC 1372025  . PMID 1389432.
Jump up ^ Peart R (1999-06-01). "Memorandum by Dr Reg Peart". Minutes of Evidence. Select Committee on Health, House of Commons, UK Parliament. Retrieved 2009-05-27.
Jump up ^ Jufe GS (Jul–Aug 2007). "[New hypnotics: perspectives from sleep physiology]". Vertex. 18 (74): 294–9. PMID 18265473.
Jump up ^ Lemmer B (2007). "The sleep–wake cycle and sleeping pills". Physiology & Behavior. 90 (2–3): 285–93. doi:10.1016/j.physbeh.2006.09.006. PMID 17049955.
Jump up ^ "Controlled Drugs and Substances Act". Canadian Department of Justice. Retrieved 2009-05-27.
Jump up ^ "FAQ - Benzodiazepines and Other Targeted Substances Regulations". Health Canada. Retrieved 28 January 2017.
Jump up ^ "Safe Prescribing of Drugs with Potential for Misuse/Diversion" (PDF). Professional Standards and Guidelines. College of Physicians and Surgeons of British Columbia. Retrieved 28 January 2017.
Jump up ^ Zlomislic, Diana. "Star obtains list of red-flagged drugs". thestar.com. Retrieved 28 January 2017. Doctors and health experts alarmed that Health Canada won’t make public its reviews of drug investigations in 2013.
Jump up ^ Blackpool NHS Primary Care Trust (1 May 2008). "Medicines Management Update" (PDF). United Kingdom National Health Service. Archived from the original (PDF) on 4 December 2010. Retrieved 2009-05-27.
Jump up ^ "List of Drugs Currently Controlled Under The Misuse of Drugs Legislation" (PDF). Misuse of Drugs Act UK. British Government. Archived from the original (PDF) on 2007-02-05. Retrieved 2009-05-27.
Jump up ^ "Opium Law" (PDF). Dutch Government. 29 November 2004. Archived from the original (PDF) on October 20, 2008. Retrieved 2009-05-27.
Jump up ^ Hong Kong Government. "DANGEROUS DRUGS ORDINANCE – SCHEDULE 1". Hong Kong Ordinances. Hong Kong: hklii.org.
Jump up ^ Lee KK, Chan TY, Chan AW, Lau GS, Critchley JA (1995). "Use and abuse of benzodiazepines in Hong Kong 1990-1993--the impact of regulatory changes". Journal of Toxicology: Clinical Toxicology. 33 (6): 597–602. doi:10.3109/15563659509010615. PMID 8523479.
Jump up ^ International Narcotics Control Board (August 2003). "List of psychotropic substances under international control" (PDF). incb.org. Archived from the original (pdf) on 2005-12-05. Retrieved 2008-12-17.
Jump up ^ International Narcotics Control Board (2003). "List of psychotropic substances under international control" (PDF). Archived from the original (PDF) on 2005-12-05. Retrieved 2008-12-17.
Jump up ^ Home Office (2005). Explanatory memorandum to the misuse of drugs and the misuse of drugs Archived December 16, 2010, at the Wayback Machine. (supply to addicts) (amendment) regulations 2005.No.2864. Accessed 20–10–03
Jump up ^ "List of drugs currently controlled under the misuse of drugs legislation" (PDF). UK Government Home Office. 2010-10-25. Retrieved 2011-01-30.
Jump up ^ Karch SB (20 December 2006). Drug Abuse Handbook (2nd ed.). United States of America: CRC Press. p. 217. ISBN 978-0-8493-1690-6.
Jump up ^ Gerada C, Ashworth M (1997). "ABC of mental health. Addiction and dependence—I: Illicit drugs". BMJ. 315 (7103): 297–300. doi:10.1136/bmj.315.7103.297. PMC 2127199  . PMID 9274553.
Jump up ^ Loxley W (2007). "Benzodiazepine use and harms among police detainees in Australia" (PDF). Trends & Issues in Crime and Criminal Justice. Canberra, A.C.T.: Australian Institute of Criminology (336). ISSN 0817-8542. Retrieved 2009-06-10.
Jump up ^ Kintz P (2007). "Bioanalytical procedures for detection of chemical agents in hair in the case of drug-facilitated crimes". Analytical and Bioanalytical Chemistry. 388 (7): 1467–74. doi:10.1007/s00216-007-1209-z. PMID 17340077.
Jump up ^ "Benzodiazepine abuse". Benzo.org.uk. Retrieved 2011-11-28.
Jump up ^ Farré M, Camí J (December 1991). "Pharmacokinetic considerations in abuse liability evaluation". British Journal of Addiction. 86 (12): 1601–6. doi:10.1111/j.1360-0443.1991.tb01754.x. PMID 1786493.
Jump up ^ Busto U, Sellers EM (1986). "Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective". Clinical Pharmacokinetics. 11 (2): 144–153. doi:10.2165/00003088-198611020-00004. PMID 3514044.
^ Jump up to: a b Kahn CM, Line S, Aiello SE, eds. (2005). The Merck Veterinary Manual (9th ed.). Wiley. ISBN 978-0-911910-50-6.
Jump up ^ Frey HH (1989). "Anticonvulsant drugs used in the treatment of epilepsy". Problems in Veterinary Medicine. 1 (4): 558–77. PMID 2520134.
Jump up ^ Podell M (1996). "Seizures in dogs". Veterinary Clinics of North America: Small Animal Practice. 26 (4): 779–809. PMID 8813750.
Jump up ^ Gross ME (2001). "Tranquilizers, α2-adrenergic agonists, and related agents". In Adams RH. Veterinary Pharmacology and Therapeutics (8th ed.). Iowa State University Press. pp. 325–33. ISBN 0-8138-1743-9.
External links[edit]
National Institute on Drug Abuse: "NIDA for Teens: Prescription Depressant Medications".* Ashton CH (2002). Benzodiazepines: how they work & how to withdraw (aka The Ashton Manual). The Ashton Manual. Retrieved 2009-06-09.
Ashton CH (2007). "Benzodiazepine equivalence table". Retrieved 2009-06-09.
Fruchtengarten L (April 1998). Ruse M, ed. "Benzodiazepines". Poisons Information Monograph (Group monograph) G008. IPCS INCHEM. Retrieved 2009-06-09.
Longo LP, Johnson B (April 2000). "Addiction: Part I. Benzodiazepines—side effects, abuse risk and alternatives". American Family Physician. 61 (7): 2121–8. PMID 10779253.
"The complete story of the benzodiazepines". The Eaton T. Fores Research Center. 2005. Archived from the original on June 5, 2009. Retrieved 2009-06-09.
"Benzodiazepines". Drugs.com.
Benzodiazepines – information from mental health charity The Royal College of Psychiatrists
"Benzodiazepines". RxList.
"benzodiazepines-oral" at medicinenet.com
pharmacy portal
[show]
v
t
e
Benzodiazepines
1,4-Benzodiazepines
2-Oxoquazepam
3-Hydroxyphenazepam
Bromazepam
Camazepam
Carburazepam
Chlordiazepoxide
Cinazepam
Cinolazepam
Clonazepam
Cloniprazepam
Clorazepate
Cyprazepam
Delorazepam
Demoxepam
Desmethylflunitrazepam
Devazepide*
Diazepam
Diclazepam
Doxefazepam
Elfazepam
Ethyl carfluzepate
Ethyl dirazepate
Ethyl loflazepate
Flubromazepam
Fletazepam
Fludiazepam
Flunitrazepam
Flurazepam
Flutemazepam
Flutoprazepam
Fosazepam
Gidazepam
Halazepam
Iclazepam
Irazepine
Kenazepine
Ketazolam
Lorazepam
Lormetazepam
Lufuradom*
Meclonazepam
Medazepam
Menitrazepam
Metaclazepam
Motrazepam
N-Desalkylflurazepam
Nifoxipam
Nimetazepam
Nitrazepam
Nitrazepate
Nordazepam
Nortetrazepam
Oxazepam
Phenazepam
Pinazepam
Pivoxazepam
Prazepam
Proflazepam
Quazepam
QH-II-66
Reclazepam
RO4491533*
Ro5-4864*
Sulazepam
Temazepam
Tetrazepam
Tifluadom*
Tolufazepam
Triflunordazepam
Tuclazepam
Uldazepam
1,5-Benzodiazepines
Arfendazam
Clobazam
CP-1414S
Lofendazam
Triflubazam
2,3-Benzodiazepines*
Girisopam
GYKI-52466
GYKI-52895
Nerisopam
Talampanel
Tofisopam
Triazolobenzodiazepines
Adinazolam
Alprazolam
Clonazolam
Estazolam
Flubromazolam
Flunitrazolam
Nitrazolam
Pyrazolam
Triazolam
Imidazobenzodiazepines
Bretazenil
Climazolam
EVT-201
FG-8205
Flumazenil
Imidazenil
123I-Iomazenil
L-655,708
Loprazolam
Midazolam
PWZ-029
Remimazolam
Ro15-4513
Ro48-6791
Ro48-8684
Ro4938581
Sarmazenil
SH-053-R-CH3-2′F
Oxazolobenzodiazepines
Cloxazolam
Flutazolam
Haloxazolam
Mexazolam
Oxazolam
Thienodiazepines
Bentazepam
Clotiazepam
Thienotriazolodiazepines
Brotizolam
Ciclotizolam
Deschloroetizolam
Etizolam
Israpafant*
JQ1*
Metizolam
Thienobenzodiazepines*
Olanzapine
Telenzepine
Pyridodiazepines
Lopirazepam
Pyridotriazolodiazepines
Zapizolam
Pyrazolodiazepines
Razobazam*
Ripazepam
Zolazepam
Zomebazam
Zometapine*
Pyrrolodiazepines
Premazepam
Tetrahydroisoquinobenzodiazepines
Clazolam
Pyrrolobenzodiazepines*
Anthramycin
Benzodiazepine prodrugs
Avizafone
Rilmazafone
* atypical activity profile (not GABAA receptor ligands)
[show]
v
t
e
Treatment of drug dependence (N07B)
Nicotine dependence
Bupropion
Cytisine
Lobeline
Mecamylamine
Varenicline
AA (Clonidine)
Alcohol dependence
AD inhibitor (Disulfiram
Calcium carbimide
Hydrogen cyanamide)
Acamprosate
Opioid antagonists (Naltrexone
Nalmefene)
Topiramate
AA (Clonidine)
Baclofen
Metadoxine
Phenibut
Opioid dependence
AA (Clonidine
Lofexidine)
Ibogaine
Opioids
Buprenorphine (+naloxone)
Levacetylmethadol
Methadone
Dihydrocodeine
Dihydroetorphine
Hydromorphone (extended-release)
Morphine (extended-release)
Opioid antagonists (Naltrexone
Nalmefene)
Benzodiazepine dependence
AA (Clonidine)
Benzodiazepines (Diazepam
Lorazepam
Chlordiazepoxide
Oxazepam)
Barbiturates (Phenobarbital)
Research
Salvia divinorum
[show]
v
t
e
Anticonvulsants (N03)
GABAergics
GABAAR PAMs
Barbiturates: Barbexaclone
Metharbital
Methylphenobarbital
Pentobarbital
Phenobarbital#
Primidone; Carbamates: Felbamate; Benzodiazepines: Clobazam
Clonazepam
Clorazepate
Diazepam#
Lorazepam#
Midazolam
Nimetazepam
Nitrazepam
Temazepam; Others: Bromide (potassium bromide, sodium bromide)
Imepitoin
Paraldehyde
Stiripentol
GABA-T inhibitors
Fatty acids (and related): Valproate
Valpromide
Valproate pivoxil
Vigabatrin
Others
GABAR agonists: Progabide; GAT-1 inhibitors: Tiagabine
Channel
modulators
Sodium blockers
Hydantoins: Ethotoin
Fosphenytoin
Mephenytoin
Phenytoin#; Ureides: Acetylpheneturide
Chlorphenacemide
Phenacemide‡
Pheneturide; Fatty acids: Valproate
Valpromide
Valproate pivoxil; Carboxamides: Carbamazepine#
Eslicarbazepine acetate
Oxcarbazepine; Others: Lacosamide
Lamotrigine#
Rufinamide
Topiramate
Zonisamide
Calcium blockers
Oxazolidinediones: Ethadione
Paramethadione
Trimethadione; Succinimides: Ethosuximide#
Mesuximide
Phensuximide; Gabapentinoids: Gabapentin
Pregabalin; Others: Imepitoin
Lamotrigine#
Topiramate
Zonisamide
Potassium openers
Retigabine
Others
CA inhibitors
Sulfonamides: Acetazolamide
Ethoxzolamide
Sultiame
Topiramate
Zonisamide
Others
Albutoin
Beclamide
Brivaracetam
Etiracetam
Levetiracetam
Perampanel
#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III
[show]
v
t
e
Anxiolytics (N05B)
5-HT1AR agonists
Buspirone
Gepirone†
Tandospirone
GABAAR PAMs
Benzodiazepines: Adinazolam
Alprazolam
Bromazepam
Camazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Clotiazepam
Cloxazolam
Diazepam#
Ethyl loflazepate
Etizolam
Fludiazepam
Halazepam
Ketazolam
Lorazepam#
Medazepam
Nordazepam
Oxazepam
Pinazepam
Prazepam; Others: Alpidem‡
Barbiturates (e.g., phenobarbital)
Carbamates (e.g., meprobamate)
Chlormezanone‡
Ethanol (alcohol)
Etifoxine
Imepitoin; Herbs:
Kava
Skullcap
Valerian
Gabapentinoids
(α2δ VDCC blockers)
Gabapentin
Gabapentin enacarbil
Phenibut
Pregabalin
Antidepressants
SSRIs (e.g., escitalopram)
SNRIs (e.g., duloxetine)
SARIs (e.g., trazodone)
TCAs (e.g., clomipramine)
TeCAs (e.g., mirtazapine)
MAOIs (e.g., phenelzine); Others: Agomelatine
Bupropion
Tianeptine
Vilazodone
Vortioxetine
Sympatholytics
(Antiadrenergics)
Alpha-1 blockers (e.g., prazosin)
Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine)
Beta blockers (e.g., propranolol)
Others
Benzoctamine
Cannabidiol
Cycloserine
Fabomotizole
Hydroxyzine
Kanna
Lavender
Lorpiprazole
Mebicar
Mepiprazole
Nicotine
Opipramol
Oxaflozane‡
Phenaglycodol
Phenibut
Picamilon
Selank
Tiagabine
Tofisopam
Validolum
#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III
[show]
v
t
e
Hypnotics/sedatives (N05C)
GABAA
Alcohols
2M2B
Chloralodol
Ethanol (alcohol)
Ethchlorvynol
Methylpentynol
Trichloroethanol
Barbiturates
Allobarbital
Amobarbital
Aprobarbital
Barbital
Butabarbital
Butobarbital
Cyclobarbital
Ethallobarbital
Heptabarb
Hexobarbital
Mephobarbital
Methohexital
Narcobarbital
Pentobarbital
Phenallymal
Phenobarbital
Propylbarbital
Proxibarbal
Reposal
Secobarbital
Talbutal
Thiamylal
Thiopental
Thiotetrabarbital
Vinbarbital
Vinylbital
Benzodiazepines
Brotizolam
Cinolazepam
Climazolam
Doxefazepam
Estazolam
Flunitrazepam
Flurazepam
Flutoprazepam
Lorazepam
Loprazolam
Lormetazepam
Midazolam
Nimetazepam
Nitrazepam
Phenazepam
Quazepam
Temazepam
Triazolam
Carbamates
Carisoprodol
Emylcamate
Ethinamate
Hexapropymate
Meprobamate
Methocarbamol
Phenprobamate
Procymate
Tybamate
Imidazoles
Etomidate
Metomidate
Propoxate
Monoureides
Acecarbromal
Apronal (apronalide)
Bromisoval
Capuride
Carbromal
Ectylurea
Neuroactive steroids
Acebrochol
Allopregnanolone
Alphadolone
Alphaxolone
Eltanolone
Hydroxydione
Minaxolone
Progesterone
Nonbenzodiazepines
Eszopiclone
Indiplon
Lirequinil
Necopidem
Pazinaclone
Saripidem
Suproclone
Suriclone
Zaleplon
Zolpidem
Zopiclone
Phenols
Propofol
Piperidinediones
Glutethimide
Methyprylon
Pyrithyldione
Piperidione
Quinazolinones
Afloqualone
Cloroqualone
Diproqualone
Etaqualone
Mebroqualone
Mecloqualone
Methaqualone
Methylmethaqualone
Nitromethaqualone
Others
Acetophenone
Acetylglycinamide chloral hydrate
Bromide compounds
Lithium bromide
Potassium bromide
Sodium bromide
Centalun
Chloral betaine
Chloral hydrate
Chloralose
Clomethiazole
Dichloralphenazone
Gaboxadol
Kavalactones
Loreclezole
Paraldehyde
Petrichloral
Sulfonylalkanes
Sulfonmethane (sulfonal)
Tetronal
Trional
Triclofos
Sesquiterpene
Isovaleramide
Isovaleric acid
Valerenic acid
GABAB
1,4-Butanediol
4-Fluorophenibut
Aceburic acid
Baclofen
GABOB
GHB (sodium oxybate)
GBL
GVL
Phenibut
Tolibut
H1
Antihistamines
Captodiame
Cyproheptadine
Diphenhydramine
Doxylamine
Hydroxyzine
Methapyrilene
Perlapine
Pheniramine
Promethazine
Propiomazine
Antidepressants
Serotonin antagonists and reuptake inhibitors
Etoperidone
Nefazodone
Trazodone
Tricyclic antidepressants
Amitriptyline
Doxepin
Trimipramine, etc.
Tetracyclic antidepressants
Mianserin
Mirtazapine, etc.
Antipsychotics
Typical antipsychotics
Chlorpromazine
Thioridazine, etc.
Atypical antipsychotics
Olanzapine
Quetiapine
Risperidone, etc.
α2-Adrenergic
Clonidine
Detomidine
Dexmedetomidine
Lofexidine
Medetomidine
Romifidine
Tizanidine
Xylazine
5-HT2A
Antidepressants
Trazodone
Tricyclic antidepressants
Amitriptyline
Doxepin
Trimipramine, etc.
Tetracyclic antidepressants
Mianserin
Mirtazapine, etc.
Antipsychotics
Typical antipsychotics
Chlorpromazine
Thioridazine, etc.
Atypical antipsychotics
Olanzapine
Quetiapine
Risperidone, etc.
Others
Niaprazine
Melatonin
Agomelatine
Melatonin
Ramelteon
Tasimelteon
Orexin
Almorexant
Filorexant
Suvorexant
α2δ VDCC
Gabapentin
Gabapentin enacarbil
Mirogabalin
Phenibut
Pregabalin
Others
Cannabidiol
Cannabis
Chlorophenylalkyldiols
Fenpentadiol
Metaglycodol
Phenaglycodol
Diethylpropanediol
Evoxine
Fenadiazole
Guaifenesin-related muscle relaxants
Chlorphenesin
Mephenesin
Mephenoxalone
Metaxalone
Methocarbamol
Opioids (e.g., morphine)
Passion flower
Scopolamine
Trazodone
UMB68
Valnoctamide
[show]
v
t
e
Insomnia pharmacotherapies
GABAAR PAMs
Benzodiazepines: Brotizolam
Cinolazepam
Climazolam
Clorazepate
Doxefazepam
Estazolam
Etizolam
Flunitrazepam
Flurazepam
Flutoprazepam
Haloxazolam
Loprazolam
Lormetazepam
Midazolam
Nimetazepam
Nitrazepam
Quazepam
Temazepam
Triazolam; Nonbenzodiazepines/Z-drugs: Eszopiclone
Zaleplon
Zolpidem
Zopiclone; Others: Alcohols (e.g., ethchlorvynol, amylene hydrate, ethanol)
Barbiturates (e.g., amobarbital, pentobarbital, phenobarbital, secobarbital)
Bromides (e.g., potassium bromide, sodium bromide)
Carbamates (e.g., meprobamate)
Chloral hydrate
Clomethiazole
Kava
Paraldehyde
Piperidinediones (e.g., glutethimide)
Quinazolinones (e.g., methaqualone)
Sulfonmethane
Valerian
Antihistamines
(H1R inverse agonists)
Alimemazine
Captodiame
Dimenhydrinate
Diphenhydramine
Doxylamine
Etodroxizine
Hydroxyzine
Meclizine
Methapyrilene
Pheniramine
Phenyltoloxamine
Pimethixene
Promethazine
Propiomazine
Pyrilamine
TCAs (e.g., amitriptyline, doxepin, trimipramine)
TeCAs (e.g., mirtazapine)
Triprolidine
OXR antagonists
Almorexant§
Filorexant§
Lemborexant§
Suvorexant
MTR agonists
Agomelatine
Melatonin
Ramelteon
Tasimelteon
Miscellaneous
Antipsychotics (e.g., quetiapine, olanzapine, chlorpromazine)
Ashwagandha
Benzoctamine
Cannabinoids (e.g., cannabis, dronabinol (THC), nabilone)
Chamomile
Fenadiazole
Gabapentinoids (e.g., gabapentin, pregabalin, phenibut)
Hops
Lavender
Menthyl isovalerate
Niaprazine
Opioids (e.g., hydrocodone, oxycodone, morphine)
Passion flower
Scopolamine
Serotonin precursors (tryptophan, 5-HTP)
Sodium oxybate (GHB)
Sympatholytics (e.g., clonidine, guanfacine)
TCAs (e.g., amitriptyline, doxepin, trimipramine)
TeCAs (e.g., mirtazapine)
Theanine
Trazodone
Valnoctamide
[show]
v
t
e
GABAA receptor positive modulators
Alcohols
Brometone
Butanol
Chloralodol
Chlorobutanol (cloretone)
Ethanol (alcohol) (alcoholic drink)
Ethchlorvynol
Isobutanol
Isopropanol
Menthol
Methanol
Methylpentynol
Pentanol
Petrichloral
Propanol
tert-Butanol (2M2P)
tert-Pentanol (2M2B)
Tribromoethanol
Trichloroethanol
Triclofos
Trifluoroethanol
Barbiturates
(-)-DMBB
Allobarbital
Alphenal
Amobarbital
Aprobarbital
Barbexaclone
Barbital
Benzobarbital
Benzylbutylbarbiturate
Brallobarbital
Brophebarbital
Butabarbital/Secbutabarbital
Butalbital
Buthalital
Butobarbital
Butallylonal
Carbubarb
Crotylbarbital
Cyclobarbital
Cyclopentobarbital
Difebarbamate
Enallylpropymal
Ethallobarbital
Eterobarb
Febarbamate
Heptabarb
Heptobarbital
Hexethal
Hexobarbital
Metharbital
Methitural
Methohexital
Methylphenobarbital
Narcobarbital
Nealbarbital
Pentobarbital
Phenallymal
Phenobarbital
Phetharbital
Primidone
Probarbital
Propallylonal
Propylbarbital
Proxibarbital
Reposal
Secobarbital
Sigmodal
Spirobarbital
Talbutal
Tetrabamate
Tetrabarbital
Thialbarbital
Thiamylal
Thiobarbital
Thiobutabarbital
Thiopental
Thiotetrabarbital
Valofane
Vinbarbital
Vinylbital
Benzodiazepines
2-Oxoquazepam
3-Hydroxyphenazepam
Adinazolam
Alprazolam
Arfendazam
Avizafone
Bentazepam
Bretazenil
Bromazepam
Brotizolam
Camazepam
Carburazepam
Chlordiazepoxide
Ciclotizolam
Cinazepam
Cinolazepam
Clazolam
Climazolam
Clobazam
Clonazepam
Clonazolam
Cloniprazepam
Clorazepate
Clotiazepam
Cloxazolam
CP-1414S
Cyprazepam
Delorazepam
Demoxepam
Diazepam
Diclazepam
Doxefazepam
Elfazepam
Estazolam
Ethyl carfluzepate
Ethyl dirazepate
Ethyl loflazepate
Etizolam
EVT-201
FG-8205
Fletazepam
Flubromazepam
Flubromazolam
Fludiazepam
Flunitrazepam
Flunitrazolam
Flurazepam
Flutazolam
Flutemazepam
Flutoprazepam
Fosazepam
Gidazepam
Halazepam
Haloxazolam
Iclazepam
Imidazenil
Irazepine
Ketazolam
Lofendazam
Lopirazepam
Loprazolam
Lorazepam
Lormetazepam
Meclonazepam
Medazepam
Menitrazepam
Metaclazepam
Mexazolam
Midazolam
Motrazepam
N-Desalkylflurazepam
Nifoxipam
Nimetazepam
Nitrazepam
Nitrazepate
Nitrazolam
Nordazepam
Nortetrazepam
Oxazepam
Oxazolam
Phenazepam
Pinazepam
Pivoxazepam
Prazepam
Premazepam
Proflazepam
Pyrazolam
QH-II-66
Quazepam
Reclazepam
Remimazolam
Rilmazafone
Ripazepam
Ro48-6791
Ro48-8684
SH-053-R-CH3-2′F
Sulazepam
Temazepam
Tetrazepam
Tolufazepam
Triazolam
Triflubazam
Triflunordazepam (Ro5-2904)
Tuclazepam
Uldazepam
Zapizolam
Zolazepam
Zomebazam
Carbamates
Carisbamate
Carisoprodol
Clocental
Cyclarbamate
Difebarbamate
Emylcamate
Ethinamate
Febarbamate
Felbamate
Hexapropymate
Lorbamate
Mebutamate
Meprobamate
Nisobamate
Pentabamate
Phenprobamate
Procymate
Styramate
Tetrabamate
Tybamate
Flavonoids
6-Methylapigenin
Ampelopsin (dihydromyricetin)
Apigenin
Baicalein
Baicalin
Catechin
EGC
EGCG
Hispidulin
Linarin
Luteolin
Rc-OMe
Skullcap constituents (e.g., baicalin)
Wogonin
Imidazoles
Etomidate
Metomidate
Propoxate
Kava constituents
10-Methoxyyangonin
11-Methoxyyangonin
11-Hydroxyyangonin
Desmethoxyyangonin
11-Methoxy-12-hydroxydehydrokavain
7,8-Dihydroyangonin
Kavain
5-Hydroxykavain
5,6-Dihydroyangonin
7,8-Dihydrokavain
5,6,7,8-Tetrahydroyangonin
5,6-Dehydromethysticin
Methysticin
7,8-Dihydromethysticin
Yangonin
Monoureides
Acecarbromal
Apronal (apronalide)
Bromisoval
Carbromal
Capuride
Ectylurea
Neuroactive steroids
Acebrochol
Allopregnanolone (brexanolone)
Alfadolone
Alfaxalone
3α-Androstanediol
Androstenol
Androsterone
Certain anabolic-androgenic steroids
Cholesterol
DHDOC
3α-DHP
5α-DHP
5β-DHP
DHT
Etiocholanolone
Ganaxolone
Hydroxydione
Minaxolone
ORG-20599
ORG-21465
P1-185
Pregnanolone (eltanolone)
Progesterone
Renanolone
SAGE-105
SAGE-217
SAGE-324
SAGE-516
SAGE-689
SAGE-872
Testosterone
THDOC
Nonbenzodiazepines
β-Carbolines: Abecarnil
Gedocarnil
Harmane
SL-651,498
ZK-93423
Cyclopyrrolones: Eszopiclone
Pagoclone
Pazinaclone
Suproclone
Suriclone
Zopiclone
Imidazopyridines: Alpidem
DS-1
Necopidem
Saripidem
Zolpidem
Pyrazolopyrimidines: Divaplon
Fasiplon
Indiplon
Lorediplon
Ocinaplon
Panadiplon
Taniplon
Zaleplon
Others: Adipiplon
CGS-8216
CGS-9896
CGS-13767
CGS-20625
CL-218,872
CP-615,003
CTP-354
ELB-139
GBLD-345
Imepitoin
JM-1232
L-838,417
Lirequinil (Ro41-3696)
NS-2664
NS-2710
NS-11394
Pipequaline
ROD-188
RWJ-51204
SB-205,384
SX-3228
TGSC01AA
TP-003
TPA-023
TP-13
U-89843A
U-90042
Viqualine
Y-23684
Phenols
Fospropofol
Propofol
Thymol
Piperidinediones
Glutethimide
Methyprylon
Piperidione
Pyrithyldione
Pyrazolopyridines
Cartazolate
Etazolate
ICI-190,622
Tracazolate
Quinazolinones
Afloqualone
Cloroqualone
Diproqualone
Etaqualone
Mebroqualone
Mecloqualone
Methaqualone
Methylmethaqualone
Nitromethaqualone
SL-164
Volatiles/gases
Acetone
Acetophenone
Acetylglycinamide chloral hydrate
Aliflurane
Benzene
Butane
Butylene
Centalun
Chloral
Chloral betaine
Chloral hydrate
Chloroform
Cryofluorane
Desflurane
Dichloralphenazone
Dichloromethane
Diethyl ether
Enflurane
Ethyl chloride
Ethylene
Fluroxene
Gasoline
Halopropane
Halothane
Isoflurane
Kerosine
Methoxyflurane
Methoxypropane
Nitric oxide
Nitrogen
Nitrous oxide
Norflurane
Paraldehyde
Propane
Propylene
Roflurane
Sevoflurane
Synthane
Teflurane
Toluene
Trichloroethane (methyl chloroform)
Trichloroethylene
Vinyl ether
Others/unsorted
3-Hydroxybutanal
α-EMTBL
AA-29504
Avermectins (e.g., ivermectin)
Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide)
Carbamazepine
Chloralose
Chlormezanone
Clomethiazole
DEABL
Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine))
DS2
Efavirenz
Etazepine
Etifoxine
Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid)
Fluoxetine
Flupirtine
Hopantenic acid
Lanthanum
Lavender oil
Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol)
Loreclezole
Menthyl isovalerate (validolum)
Monastrol
Niacin
Nicotinamide (niacinamide)
Org 25,435
Phenytoin
Propanidid
Retigabine (ezogabine)
Safranal
Seproxetine
Stiripentol
Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional)
Terpenoids (e.g., borneol)
Topiramate
Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol)
Unsorted benzodiazepine site positive modulators: α-Pinene
MRK-409 (MK-0343)
TCS-1105
TCS-1205
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators
Authority control
LCCN: sh85013239
GND: 4005552-8
BNF: cb120015571 (data)
BNE: XX529163
Retrieved from "https://en.wikipedia.org/w/index.php?title=Benzodiazepine&oldid=818984051"
Categories:
Benzodiazepines
Chemical classes of psychoactive drugs
GABAA receptor positive allosteric modulators
Glycine receptor antagonists
Sedatives
Hypnotics
Hidden categories:
CS1 French-language sources (fr)
CS1 maint: Uses authors parameter
Articles with inconsistent citation formats
Pages with DOIs inactive since 2017
CS1 Portuguese-language sources (pt)
CS1 Japanese-language sources (ja)
Webarchive template wayback links
Good articles
Articles needing additional medical references from May 2015
All articles needing additional references
Articles needing additional medical references from August 2016
Wikipedia articles with LCCN identifiers
Wikipedia articles with GND identifiers
Wikipedia articles with BNF identifiers
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
Afrikaans
العربية
বাংলা
Български
Bosanski
Català
Čeština
Dansk
Deutsch
Ελληνικά
Español
Esperanto
Euskara
فارسی
Français
Gaeilge
Galego
한국어
Bahasa Indonesia
Italiano
עברית
Kurdî
Latina
Latviešu
Magyar
Nederlands
日本語
Norsk
Norsk nynorsk
Polski
Português
Română
Русский
Simple English
Slovenščina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
ไทย
Türkçe
Українська
Tiếng Việt
中文
Edit links
This page was last edited on 6 January 2018, at 18:48.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

value: mw-page-base noprint

value: mw-head-base noprint

value: This is a good article. Follow the link for more information.

attr: class id

value: firstHeading firstHeading en

value: siteSub noprint

value: jump-to-nav mw-jump

attr: href class title

value:
/wiki/Benzo_Fury_(disambiguation)
mw-redirect mw-disambig
Benzo Fury (disambiguation)

value:
note
hatnote navigation-not-searchable

tag: th

value: padding:0.2em 0.4em 0.2em;font-size:145%;line-height:1.2em;background: #CCF

tag: tr

value: Chemical structure diagram of a benzene ring fused to a diazepine ring. Another benzene ring is attached to the bottom of the diazepine ring via a single line. Attached to the first benzene ring is a side chain labeled R7; to the second, a side chain labeled R2'; and attached to the diazepine ring, two side chains labeled R1 and R2.

attr: href class

value:
/wiki/Benzodiazepine_misuse
mw-redirect
Benzodiazepine misuse

value: float:right;clear:right;width:22.0em;margin:0 0 1.0em 1.0em;background:#f9f9f9;border:1px solid #aaa;padding:0.2em;border-spacing:0.4em 0;text-align:center;line-height:1.4em;font-size:88%

value: Role of chance in scientific discoveries

value:
/wiki/Hoffmann%E2%80%93La_Roche
mw-redirect
Hoffmann–La Roche

value:
/wiki/Minor_tranquilizers
mw-redirect
Minor tranquilizers

value:
/wiki/Alcohol_withdrawal
mw-redirect
Alcohol withdrawal

value:
/wiki/Paradoxical_effect
mw-redirect
Paradoxical effect

value:
/wiki/Cleft_palate
mw-redirect
Cleft palate

attr: alt src width height class srcset data-file-width data-file-height

value: Two 10 mL bottles labeled Midazolam. The bottle on the left has a label in red and says 1 mg/mL; the one on the right is in green and says 5 mg/mL. Both bottles have much fine print.

value:
/wiki/Anxiety_disorders
mw-redirect
Anxiety disorders

value:
/wiki/Drug_dependence
mw-redirect
Drug dependence

value: College of Physicians and Surgeons of British Columbia

value: National Institute for Health and Clinical Excellence

value:
/wiki/Placebo-controlled_studies
mw-redirect
Placebo-controlled studies

value:
/wiki/Rebound_anxiety
mw-redirect
Rebound anxiety

value:
/wiki/First-line_treatment
mw-redirect
First-line treatment

value:
/wiki/Cognitive_behavioural_therapy
mw-redirect
Cognitive behavioural therapy

value: Edit section: Generalized anxiety disorder

value:
/wiki/Rebound_insomnia
mw-redirect
Rebound insomnia

value: Agency for Healthcare Research and Quality

value:
/wiki/Traffic_collisions
mw-redirect
Traffic collisions

value:
/wiki/Buccal_mucosa
mw-redirect
Buccal mucosa

value:
/wiki/Respiratory_depression
mw-redirect
Respiratory depression

value:
/wiki/Dental_phobia
mw-redirect
Dental phobia

value:
/wiki/Lithium_pharmacology
mw-redirect
Lithium pharmacology

value:
/wiki/Personality_disorders
mw-redirect
Personality disorders

value:
/wiki/Paradoxical_reactions
mw-redirect
Paradoxical reactions

value: Food and Drug Administration (United States)

value:
/wiki/Cleft_lip_and_palate
mw-redirect
Cleft lip and palate

value:
/wiki/Floppy_infant_syndrome
mw-redirect
Floppy infant syndrome

value:
/wiki/Neonatal_withdrawal_syndrome
mw-redirect
Neonatal withdrawal syndrome

value:
/wiki/Hip_fractures
mw-redirect
Hip fractures

value:
/wiki/Anxiety_syndromes
mw-redirect
Anxiety syndromes

value:
/wiki/Euphoria_(emotion)
mw-redirect
Euphoria (emotion)

value:
/wiki/Liver_toxicity
mw-redirect
Liver toxicity

value:
/wiki/Cognitive_impairment
mw-redirect
Cognitive impairment

value:
/wiki/Impulse_control
mw-redirect
Impulse control

value: Edit section: Long-term worsening of psychiatric symptoms

value: White bottle with red and black labels on a blue pad atop a desk. Also on the pad are seven small pills.

value:
/wiki/Benzodiazepine_withdrawal
mw-redirect
Benzodiazepine withdrawal

value:
/wiki/Post-acute_withdrawal_syndrome
mw-redirect
Post-acute withdrawal syndrome

value: Edit section: Withdrawal symptoms and management

value: White bottle on blue pad atop a desk. The bottle cap is off, and is upside down on the pad in front of the bottle. In the cap are a dozen black-and-yellow capsules.

value:
/wiki/Elimination_half-life
mw-redirect
Elimination half-life

value:
/wiki/Active_metabolites
mw-redirect
Active metabolites

value:
/wiki/Environmental_stresses
mw-redirect
Environmental stresses

value:
/wiki/Cross_tolerant
mw-redirect
Cross tolerant

value: Edit section: Controversial associations

value: Chemical structure of the benzodiazepine flumazenil, which contains an imidazole ring fused to positions one and two, a methyl group at position four, an exocylic carbonyl oxygen atom a position five, and a fluorine atom at position seven.

value:
/wiki/Tricyclic_antidepressants
mw-redirect
Tricyclic antidepressants

value:
/wiki/Slurred_speech
mw-redirect
Slurred speech

value:
/wiki/Cardiorespiratory_arrest
mw-redirect
Cardiorespiratory arrest

value:
/wiki/Antifungal_medication
mw-redirect
Antifungal medication

value: Figure of the GABAA receptor complex where the five subunits (two alpha, two beta, and one gamma) are symmetrically arranged in a pentagon shape about a central ion conduction pore. The location of the two GABA binding sites are located between the alpha and beta subunit, while the single benzodiazepine binding site is located between the alpha and gamma subunits.

value:
/wiki/Multiprotein_complex
mw-redirect
Multiprotein complex

value:
/wiki/Gamma-aminobutyric_acid
mw-redirect
Gamma-aminobutyric acid

value:
/wiki/Glial_cells
mw-redirect
Glial cells

value: Wikipedia:Identifying reliable sources (medicine)

value:
plainlinks metadata ambox ambox-content
presentation

value:
headerSort
0
columnheader button
Sort ascending

value: float: right; margin-left:15px; text-align:center

value:
/wiki/Partial_agonists
mw-redirect
Partial agonists

value:
/wiki/Rebound_effects
mw-redirect
Rebound effects

value: On the left is the chemical structure of the parent benzodiazepine ring system, which consists of a seven-membered ring containing two nitrogen atoms fused to a six-membered ring. The two nitrogen atoms are labeled one and four. On the right is the chemical structure of a pharmacologically active benzodiazepine in which alkyl, phenyl, and halogen groups attach to the one, five, and seven positions, respectively, and the carbon atom at position two is double-bonded to an exocyclic oxygen atom. The ortho and para positions of the phenyl substituent are labeled two-prime and 4-prime, respectively.

value: Superposition of the chemical structures of a benzodiazepine and nonbenzodiazepine ligand and their interactions with binding sites within the receptor.

value:
/wiki/IUPAC_nomenclature
mw-redirect
IUPAC nomenclature

value: Chemical structure diagram of a benzene ring fused to a diazepine ring. Cl is attached to the benzene; N, H, CH3, and O are attached to the diazepine.

value:
/wiki/Class-action_lawsuit
mw-redirect
Class-action lawsuit

value:
/wiki/Drugs_manufacturers
mw-redirect
Drugs manufacturers

value:
/wiki/British_law
mw-redirect
British law

value:
/wiki/Benzodiazepine_drug_misuse
mw-redirect
Benzodiazepine drug misuse

value:
/wiki/Drug_assisted_rape
mw-redirect
Drug assisted rape

value:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18175099

value:
nofollow
external text
//doi.org/10.1016%2Fj.encep.2007.05.005

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18922233

value:
nofollow
external text
//doi.org/10.4088%2FPCC.16r02037

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/28257172

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18671662

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19062773

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16639148

value:
nofollow
external text
//doi.org/10.1111%2Fjgs.13702

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26446832

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18378767

value: Category:CS1 maint: Uses authors parameter

attr: alt src title width height srcset data-file-width data-file-height

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9780123

value:
nofollow
external text
//doi.org/10.1002%2Fpds.1694

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19125401

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10707430

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10622686

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17696574

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1970816

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16400293

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14767398

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15762816

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12516310

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19122540

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17881433

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16933543

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25932596

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17853625

value:
nofollow
external text
//doi.org/10.1002%2Fpds.3951

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26711081

value:
/wiki/ABIM_Foundation
mw-redirect
ABIM Foundation

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22091502

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16156679

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22376048

value:
nofollow
external text
http://sign.ac.uk/pdf/sign70.pdf

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19298435

value:
nofollow
external text
//doi.org/10.1136%2Fbmj.315.7104.358

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9270461

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10408740

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10507746

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16623205

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8700792

value:
nofollow
external text
//doi.org/10.1016%2Fj.ccc.2009.03.003

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19576523

value:
nofollow
external text
//doi.org/10.1055%2Fs-2008-1060547

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18293248

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17607891

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9929772

value:
nofollow
external text
//doi.org/10.1185%2F030079908X261113

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18167175

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18278976

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15013244

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23633309

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17580590

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10996567

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11471763

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17876423

value:
nofollow
external text
//doi.org/10.1002%2Fmds.22254

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18925578

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18849910

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18601302

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22531198

value:
nofollow
external text
//doi.org/10.1136%2Fbmj.317.7162.839

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9748174

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9614425

value:
nofollow
external text
//doi.org/10.1176%2Fappi.ps.53.1.39

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11773648

value:
nofollow
external text
//doi.org/10.1016%2Fj.cger.2007.08.009

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18035234

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16860264

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22566242

value:
nofollow
external text
//doi.org/10.1176%2Fappi.ps.55.3.233

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15001721

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16240487

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15841867

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12919245

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17074284

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10779253

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17382831

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18929314

value:
nofollow
external text
//doi.org/10.4088%2FJCP.08m04325

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19389334

value:
nofollow
external text
//doi.org/10.1002%2Fpds.1763

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19418468

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15762814

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14731058

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18384456

value:
nofollow
external text
//doi.org/10.1192%2Fpb.26.12.460

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26256485

value:
nofollow
external text
//doi.org/10.1055%2Fs-2007-979558

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8803355

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9746445

value:
nofollow
external text
//doi.org/10.4088%2FJCP.13m08592

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24434093

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9299803

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19167197

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14580077

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16528135

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15762818

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15078112

value:
nofollow
external text
//doi.org/10.1136%2Fbmj.329.7476.1198

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15550406

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15003439

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18949648

value:
nofollow
external text
//doi.org/10.1016%2Fj.brat.2003.12.002

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15531349

value:
nofollow
external text
http://benzo.org.uk/ashpws.htm

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1675688

value:
nofollow
http://benzo.org.uk/manual/
external text

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/28865038

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26016483

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23823009

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26715389

value:
nofollow
external text
//doi.org/10.1002%2Fpds.4028

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27215827

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23220867

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22091503

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19968019

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23478657

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8847962

value:
nofollow
external text
//doi.org/10.1002%2Fijc.30443

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27667780

value:
nofollow
external text
//doi.org/10.1016%2Fj.phrs.2007.08.006

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17920927

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26717383

value:
nofollow
external text
//doi.org/10.1111%2Fijcp.12689

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26133234

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1888441

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1794007

value:
nofollow
external text
//doi.org/10.1136%2Fbmj.310.6974.219

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7866122

value:
nofollow
external text
//doi.org/10.1192%2Fbjp.163.3.386

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8104653

value:
nofollow
external text
//doi.org/10.1081%2FCLT-120030946

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15214628

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1286503

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1611650

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9397065

value:
nofollow
external text
//doi.org/10.1016%2Fj.coph.2005.10.003

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16376150

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8783370

value:
nofollow
external text
//doi.org/10.1042%2FBST0320553

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15157182

value:
nofollow
external text
//doi.org/10.1007%2FBF02741459

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9824848

value:
nofollow
external text
//doi.org/10.1007%2Fbf03345110

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12240908

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9504140

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9378234

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16780077

value: A Guide to IUPAC Nomenclature of Organic Compounds

value: International Union of Pure and Applied Chemistry

value:
/wiki/Blackwell_Science
mw-redirect
Blackwell Science

value:
nofollow
external text
//doi.org/10.1351%2Fpac199870010143

value:
/wiki/CAS_registry_number
mw-redirect
CAS registry number

value:
nofollow
external text
//doi.org/10.1007%2Fs10822-006-9059-x

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16972167

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2925017

value:
nofollow
external text
//doi.org/10.1021%2Fjm00187a001

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/34039

value:
nofollow
external text
//doi.org/10.1300%2FJ251v08n03_06

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1971487

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1389432

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18265473

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17049955

value:
/wiki/Hong_Kong_Government
mw-redirect
Hong Kong Government

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8523479

value:
nofollow
external text
//doi.org/10.1136%2Fbmj.315.7103.297

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9274553

value:
nofollow
external text
//www.worldcat.org/issn/0817-8542

value:
nofollow
external text
//doi.org/10.1007%2Fs00216-007-1209-z

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17340077

value:
nofollow
external text
http://www.benzo.org.uk/ashbzab.htm

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1786493

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3514044

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2520134

value:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8813750

value: -moz-column-width: 32em; -webkit-column-width: 32em; column-width: 32em; list-style-type: decimal;

value:
nofollow
external text
http://benzo.org.uk/bzequiv.htm

value: International Programme on Chemical Safety

value:
nofollow
external text
http://www.etfrc.com/benzos1.htm

value:
noprint metadata navbox
navigation
Portals
font-weight:bold;padding:0.4em 2em

value: nowraplinks collapsible autocollapse navbox-inner

value: navigation navbox Benzodiazepines padding:3px

value:
/wiki/Hydrogen_cyanamide
mw-redirect
Hydrogen cyanamide

value:
/wiki/Opioid_dependence
mw-redirect
Opioid dependence

value:
/wiki/Positive_allosteric_modulator
mw-redirect
Positive allosteric modulator

value:
/wiki/GABA_agonist
mw-redirect
GABA agonist

value:
/wiki/Ion_channel_modulator
mw-redirect
Ion channel modulator

value:
navbox-abovebelow
2
background: transparent; padding: 0px;

value:
/wiki/Positive_allosteric_modulators
mw-redirect
Positive allosteric modulators

value: Serotonin antagonist and reuptake inhibitors

value:
/wiki/Tetracyclic_antidepressants
mw-redirect
Tetracyclic antidepressants

value:
/wiki/Monoamine_oxidase_inhibitors
mw-redirect
Monoamine oxidase inhibitors

value:
/wiki/Alpha-2_agonist
mw-redirect
Alpha-2 agonist

value: nowraplinks collapsible collapsed navbox-inner

value:
/wiki/Neuroactive_steroid
mw-redirect
Neuroactive steroid

value:
/wiki/Isovaleric_acid
mw-redirect
Isovaleric acid

value:
/wiki/H1_receptor
mw-redirect
H1 receptor

value:
/wiki/Histamine_antagonist
mw-redirect
Histamine antagonist

value: Serotonin antagonists and reuptake inhibitors

value: Chlorophenylalkyldiol (page does not exist)

value: 2,2-Diethyl-1,3-propanediol (page does not exist)

value: Template:GABAA receptor positive modulators

value: Template talk:GABAA receptor positive modulators

value: GABAA receptor positive allosteric modulator

value:
row
navbox-group
width:1%;text-align: center;

value: (-)-5-(1,3-Dimethylbutyl)-5-ethylbarbituric acid (page does not exist)

value: Trans-6,4′-dimethoxyretrochalcone (page does not exist)

value: 10-Methoxyyangonin (page does not exist)

value: 11-Methoxyyangonin (page does not exist)

value: 11-Hydroxyyangonin (page does not exist)

value: 11-Methoxy-12-hydroxydehydrokavain (page does not exist)

value: 7,8-Dihydroyangonin (page does not exist)

value: 5,6-Dihydroyangonin (page does not exist)

value: 5,6,7,8-Tetrahydroyangonin (page does not exist)

value: 5,6-Dehydromethysticin (page does not exist)

value: 7,8-Dihydromethysticin (page does not exist)

value:
/wiki/Anabolic-androgenic_steroid
mw-redirect
Anabolic-androgenic steroid

value: Α-Ethyl-α-methylthiobutyrolactone (page does not exist)

value: 4-Chloro-N-(2-(2-thienyl)imidazo(1,2-a)pyridin-3-yl)benzamide (page does not exist)

value:
/wiki/3-methylbutanoic_acid
mw-redirect
3-methylbutanoic acid

value: Template:GABA metabolism and transport modulators

value:
nofollow
external text
https://d-nb.info/gnd/4005552-8

value: Category:Chemical classes of psychoactive drugs

value: Category:GABAA receptor positive allosteric modulators

value: Category:CS1 French-language sources (fr)

value: Category:Articles with inconsistent citation formats

value: Category:Pages with DOIs inactive since 2017

value: Category:CS1 Portuguese-language sources (pt)

value: Category:CS1 Japanese-language sources (ja)

value: Category:Webarchive template wayback links

value: Category:Articles needing additional medical references from May 2015

value: Category:All articles needing additional references

value: Category:Articles needing additional medical references from August 2016

value: Category:Wikipedia articles with LCCN identifiers

value: Category:Wikipedia articles with GND identifiers

value: Category:Wikipedia articles with BNF identifiers

value: Discussion about edits from this IP address [ctrl-alt-n]

value: A list of edits made from this IP address [ctrl-alt-y]

value: You are encouraged to create an account and log in; however, it is not mandatory

value: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

value:
/wiki/Benzodiazepine
View the content page [ctrl-alt-c]
c

value: Discussion about the content page [ctrl-alt-t]

value: p-namespaces navigation vectorTabs p-namespaces-label

value:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

value: Past revisions of this page [ctrl-alt-h]

value: p-views navigation vectorTabs p-views-label

value:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

value:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

value:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

value: Featured content – the best of Wikipedia

value: Find background information on current events

value:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

value: portal navigation p-navigation p-navigation-label

value: Guidance on how to use and edit Wikipedia

value: About the project, what you can do, where to find things

value: A list of recent changes in the wiki [ctrl-alt-r]

value: portal navigation p-interaction p-interaction-label

value: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

value:
uls-settings-trigger
Language settings
0
button
true

value: بنزوديازيبين – Arabic

value: বেঞ্জোডায়াজেপিন – Bangla

value: Бензодиазепин – Bulgarian

value: Βενζοδιαζεπίνη – Greek

value: interlanguage-link interwiki-es badge-Q17437798 badge-goodarticle

value: بنزودیازپین – Persian

value: 벤조디아제핀 – Korean

value: בנזודיאזפינים – Hebrew

value: ベンゾジアゼピン – Japanese

value: Бензодиазепины – Russian

value: Бензодиазепин – Serbian

value: เบ็นโซไดอาเซพีน – Thai

value: Бензодіазепіни – Ukrainian

value: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Benzodiazepine rootpage-Benzodiazepine skin-vector action-view